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 Lysine acetylation is a dynamic post-translational modification occurring 
ubiquitously in cells. The histone deacetylase (HDAC) family catalyzes the removal of an 
acetyl group from the ε-position of lysine residues in proteins. There are 11 metal-
dependent deacetylases tasked with the proper regulation of thousands of proteins. Thus, 
it is important to define the specificity and reactivity of each isozyme. 
 HDAC8 is a well characterized metal-dependent deacetylase that can be activated 
with Zn2+ or Fe2+ in vitro with a relatively unknown protein-substrate pool. To unveil new 
putative full- length protein substrates, we developed and optimized a chemical capture 
approach that can be used along with co-immunoprecipitation and proteomics to trap 
short-lived HDAC8-substrate interactions. Using this approach, we identified 11 potential 
HDAC8 substrates. These substrates were then validated using acetylated peptide 
mimics with an enzyme-coupled assay, determining rate constants that are at least two 
orders of magnitude faster than SMC3, one of the best in vivo validated HDAC8 protein 
substrates. Furthermore, we studied how Cornelia de Lange spectrum disorders are 
caused by HDAC8 missense mutations. Based on our results, we determined that these 
mutations can affect a variety of processes such as substrate binding, product release, 
and most interestingly, divalent metal binding; bringing to question the identity of 
HDAC8’s catalytic divalent metal ion. Finally, we have shown that the sequence specificity 
of HDAC8 towards peptide substrates is dependent on the identity of the catalytic divalent 
metal ion in addition to the immediate sequence and potentially other post-translational 
modifications. Overall, this work has provided insight into the substrate specificity and 
regulation of HDAC8 in the cell, in addition to providing a new, alternate approach for 






A General Overview 
Epigenetic regulation is a key factor in cellular homeostasis. This regulation of 
proteins is possible due to post-translational modifications (PTMs). Many of these 
modifications are both dynamic and reversible. PTMs include methylation, 
phosphorylation, ubiquitination, acetylation, sumoylation and biotinylation, among others. 
Some of these modifications, such as acetylation and methylation, were originally 
characterized on the tails of core histone proteins and regulate access to wrapped DNA 
by disrupting chromatin structure1. Lysine acetylation has garnered increasing interest in 
recent years, with a trend in publication rate that rivals that of phosphorylation2. 
A major advance in the acetylation field has been the transition from analysis of 
acetylation (both hyper- and hypoacetylation) of specific lysine residues in core histone 
tails to defining and understanding the numerous proteins that undergo acetylation 
events. Acetylation has been shown to compete and/or cooperate with other PTMs, such 
as ubiquitination3, and affect specific protein-protein interactions, protein stability, and 
                                                          
* Reproduced, in part, from Lopez, J. E., Sullivan, E. D., and Fierke, C. A., (2016) Metal-dependent 
Deacetylases: Cancer and Epigenetic Regulators. ACS Chem. Bio. 11, 706-16 
† Original text written by Jeffrey E. Lopez and Eric D. Sullivan. The text was updated and revised by Jeffrey 
E. Lopez for this thesis 
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protein-DNA interactions4. Identifying HDAC-protein interactions will lead to a better 
understanding of the acetylome, the collection of non-histone proteins that undergo 
acetylation/deacetylation, and the role of acetylation in cell regulation, growth and 
homeostasis. (Figure 1.1) 
 
Acetylation is an enzyme catalyzed and reversible PTM in which an acetyl group 
is attached to the Nε -position of a lysine side chain. Lysine acetyltransferases (KATs) 
catalyze acetylation of lysine side chains using acetyl-CoA as a cofactor, and metal-
dependent deacetylases (HDACs) catalyze hydrolysis of the acetyl moiety to generate 
lysine and acetate. Traditionally, HDACs have been described as transcriptional 
repressors since they change the recruitment and interactions of many proteins, including 
bromodomain-containing proteins, MEF2-binding proteins and domains, to histone tails. 
Figure 1.1: Acetylation is critical for regulation and proper cellular function 
Lysine acetyltransferases (KATs) and histone deacetylases (HDACs) maintain acetylation to optimal 
levels. Acetylation regulates essential cellular processes such as DNA repair, chromatin and actin 
remodeling and proteins that serve as checkpoints during the cell cycle. 
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They are also involved in chromatin compaction1. However, acetylation and deacetylation 
of many non-histone proteins have now been discovered. In fact, currently, over 6000 
acetylation sites have been discovered in the mammalian proteome, with many more 
being discovered through proteomics, computational and modeling analyses5.  
Considering these many non-histone HDAC targets, a more suitable name for these 
enzymes would be acetyl-lysine deacetylases, or acKDACs. Aberrant regulation of 
protein acetylation has been observed in various types of cancers including prostate6, 
breast7, and colon8 among others, in addition to a variety of diseases, such as Cornelia 
de Lange-like Spectrum diseases (CdLS)9, Huntington’s disease10, and inflammation11. 
 The increasingly evident role and overexpression of HDACs in cancer has made 
them an interesting and attractive anticancer target. Current research shows that there 
are multiple mechanisms by which acetylation affects cancer development using HDAC 
inhibitors (HDACi) such as inducing cell growth, differentiation, senescence, and death of 
non-cancerous cells and tissues12,13. Several HDAC inhibitors have been developed to 
examine and combat these mechanisms; however, the current clinically approved 
compounds do not possess isozyme selectivity. Three pan-HDAC inhibitors - 
suberoylanilide hydroxamic acid (SAHA)14, Romidepsin (cyclic peptide)14, and belinostat 
(hydroxamic acid)15 – have been approved by the FDA for treatment of T-cell lymphomas, 
and a fourth inhibitor, panabinostat (hydroxamic acid), has recently been approved for 
multiple myeloma treatment16. 
 Studies have demonstrated that pan-HDACi’s can also be used to increase the 
effectiveness of anticancer immunotherapy treatments. In one case, T-cell survival was 
enhanced due to prevention of activation-induced cell death by lymphocytes12,17. 
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However, these effects vary significantly and can produce a variety of undesirable side 
effects. Additionally, HDACi’s have been used to enhance vaccine strategies; namely, 
mice vaccinated with melanomal cells that have been pretreated with trichostatin A (TSA), 
a potent hydroxamic acid, show an increase in immune response towards additional 
tumors, effectively enhancing their tumor specific immunity mechanisms11. 
 HDACs are divided into four different classes based on their phylogeny and 
sequence homology to yeast orthologs13. Class I, which shares homology with Rpd3, 
consists of HDACs 1, 2, 3, and 8. Class II, with homology to Hda1, can be divided into 
two subclasses – IIa (HDACs 4, 7, and 9) and IIb (HDACs 6 and 10). Class III, with 
homology to the Sir2 family, is known as the sirtuins and utilizes NAD+ as a cofactor. 
Class IV, which shares homology with both class I and class II, consists solely of 
HDAC11. Classes I, II and IV are metal-dependent HDACs that use a divalent metal-
water as a nucleophile during catalysis, which is activated by a general acid-base 
mechanism (Figure 1.2)18. In addition, the activity of HDACs can be further regulated by 
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Metal-dependent HDACs share common sequence motifs (Figure 1.3), including 
a deacetylase domain that is comprised of an arginase-deacetylase fold, consisting of a 
multistranded β-sheet surrounded by α-helices, and a divalent metal ion cofactor 
coordinated by an Asp-Asp-His triad20. Class I HDACs possess a deacetylase domain 
that has little sequence variation. These enzymes are localized mainly in the nucleus13, 
with the exception of HDAC8, which has been observed in the cytoplasm of smooth 
muscle cells21. Class II HDACs are shuttled between the nucleus and the cytoplasm and 
possess additional domains, such as MEF2 binding domains. HDAC6 has the largest 
Figure 1.2: General acid/base catalytic mechanism used by metal-dependent 
deacetylases 
A divalent metal ion is coordinated by a conserved Asp-Asp-His triad and one water molecule that 
functions as the nucleophile in the reaction. His143 acts as both a general acid and a general base, 
while Tyr306 and His143 stabilize the oxyanion intermediate. 
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array of domains with two deacetylase domains and a zinc finger binding domain13. Class 
II HDACs are expressed ubiquitously through the cell and generally have lower in vitro 
catalytic activity when compared to class I deacetylases. Finally, HDAC11, the sole class 
IV metal-dependent deacetylase, possesses characteristics from both class I and II 
deacetylases,  is expressed in high abundance in specific tissues such as brain, heart 
and kidney22 and has been shown to catalyze deacetylation of both methylcoumarin-
bound and non-methylcoumarin bound peptides23. 
 Crystal structures have been solved for HDAC1 (PDB: 4BKX), HDAC2 (PDB: 
3MAX), HDAC3 (PDB: 4A69), HDAC4 (PDB: 2VQM), HDAC6 (PDB: 3PHD, 5EDU, 5EEF, 
5EEI)), HDAC7 (PDB: 3C0Y; catalytic domain only), HDAC8 (2V5W), and HDAC9 (PDB: 





























Figure 1.3: Schematic comparison of the metal-dependent deacetylases 
All isozymes possess a common deacetylase domain. Class I isozymes are highly conserved and 
small. Class IIa isozymes have specific MEF2-binding/localization domains in addition to their 
conserved deacetylase domains. Class IIb isozymes contain unique domains unlike the other 
classes. Only the deacetylase domain has been identified in class IV. 
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One of the most prevalent questions in the HDAC field is the substrate selectivity 
of each isozyme. There are over 6000 validated mammalian acetylation sites5 and 18 
deacetylase isozymes (11 metal-dependent and 7 NAD+-dependent enzymes). Thus, 
defining the substrate pool for each isozyme is essential for understanding the biological 
functions of acetylation. Additionally, the substrate specificity of HDACs might be 
regulated by oxidative stress, protein-protein interactions, and other PTMs. Elucidating 
HDAC substrate specificity and regulation will provide insight into the function and control 
of acetylation sites in proteins.  
 Here, we highlight some functions of each of the metal-dependent deacetylase 
classes regarding epigenetic regulation and homeostasis, and how 
acetylation/deacetylation plays a role in cell proliferation and growth in cancers, in 
addition to other, as of now, unknown roles. 
Class I HDACs 
 The class I HDAC subfamily is dysregulated in cancers and is the best studied 
subfamily among the metal-dependent deacetylases. Overexpression of this subclass 
has been observed in a variety of cancers such as gastric24, breast7, prostate6, and 
colon8, as well as T-cell25 and Hodgkin’s lymphoma26. 
 In most cases, upregulation of HDAC1 is associated with poor cancer prognosis27. 
Silencing of HDAC1 using siRNA knockouts results in cell cycle arrest, growth inhibition 
and induction of apoptosis in breast cancer cells28 and induction of a plasminogen 
activator in neuroblastoma cells, increasing their invasive capacity29. Mass proteomic 
analyses have revealed additional HDAC1 protein-protein interactions, ranging from 
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short-lived interaction proteins, such as IKF2, HMG box transcription factor BBX, and 
activity-dependent neuroprotector homeobox protein ADNP, to proteins with methylation-
related functions such as ARID5B to previously uncharacterized zinc-binding proteins and 
domains, such as C16orf8730. Additionally, HDAC1 has been shown to interact with the 
oncogene fusion protein PML-RAR, a protein involved in the pathogenesis of acute 
promyelocytic lymphoma (APL); HDAC1 diminishes the tumorigenic activity of PML-RAR 
by interfering with cell differentiation, impairing genetic stability, and increasing the 
renewal of progenitor cells. However, HDAC1 expression also enhances cell survival 
once they have differentiated, leading to a dual role in cancerous tissue31. 
 Immunodeficient mice have been used to evaluate the role of HDAC1 in tumor 
formation using teratomas. In these models, HDAC1 deficiency leads to partially 
undifferentiated carcinomas, upregulation of HDAC2, elevated levels of SNAIL1 
expression and delocalization of E-cadherin32. Knockouts of HDAC1 and 2 showed  
dramatic acceleration of leukomogenesis in preleukemic mice. HDAC1 knockouts also 
led to deletion of p53 and c-myc overexpression31. Additionally, Dovey et al demonstrated 
that knockouts of key components of the HDAC1/2 deacetylase complex, namely Sin3A 
and Mi2, decreased overall HDAC activity in T-cells and perturbed the differentiation of 
thymocytes into mature T lymphocytes33. Similarly, mice knockouts of HDAC1/2 showed 
that the loss of HDAC activity leads to the accumulation of thymocytes in addition to 
blocking early thymic development34. 
 The previously described protein-protein interactions have led to the proposal that 
some HDACs function in large deacetylase complexes. HDAC1 and HDAC2, together 
with histone binding proteins RBBP4 and RBBP7, DNA/chromatin recognition motifs, and 
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transcription factors form core deacetylase complexes that help localize HDAC1 and 
HDAC2 to chromatin35.  
 HDAC2 is overexpressed in lung cancer tissues and mesenchymal tumors, 
suggesting that it is an effector for these diseases. Silencing of HDAC2 using siRNA leads 
to an increase in p53 DNA binding activity, Bax activation and Bcl2 suppression36. These 
changes in Bax activation and Bcl2 suppression are consistent with suppressed 
expression of cyclin E2, cyclin D1, and CDK2, blocking cell proliferation and inducing 
apoptosis37. Truncations of HDAC2 have been detected frequently in cancers38 and 
knockouts of both HDAC1 and HDAC2 prompt TRAIL-induced apoptosis in chronic 
lymphocytic leukemia (CLL), indicating a level of cooperativity between these two 
isozymes39. Using mutant fibroblasts that are HDAC2-deficient, Zimmerman et al 
demonstrated a lack of response to insulin-like growth factors (IGFs) when compared to 
wild type cells, showing a potential link between HDACs and IGFs40. Mice models lacking 
HDAC1 and with a single HDAC2 allele developed a lethal pathology within 3 months, 
likely due to neoplastic transformation of immature T-cells33. Additionally, mutant mice 
with an inactive HDAC2 mutant exhibited a 25% decrease in overall body size and 
reduced cell number and thickness of intestinal mucosa40. 
 Knockouts of HDAC3 in promyelocytic leukemia cells restore retinoic acid 
dependent gene expression, primarily due to loss of interactions between HDAC3, the 
nuclear corepressor NCoR, and PML-RARalpha fusion protein41. The best understood 
example of HDAC3 function is repression of retinoic acid and thyroid hormone receptors, 
which can modulate p53 expression42. HDAC3, along with HDAC1 and HDAC2, is often 
expressed in high levels in renal, colorectal, and gastric cancer26,43. High expression of 
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HDAC3 has also been observed in eight different pancreatic cancer cell lines and 
potentially generates a postinduction repression of p53, p27, and Bax genes through 
deacetylation of lysine 9 (K9) of histone H342. Additionally, HDAC3 depletion in mouse 
liver upregulates lipogenic genes and causes histone hyperacetylation, leading to 
hepatostaetosis44. However, expression of inactive HDAC3 mutant proteins in these 
knockout mice almost completely rescues the metabolic and gene transcription 
alterations, suggesting that HDAC3 plays important non-deacetylase roles, such as 
protein-protein interaction signaling. Consistent with this, mice knockouts of the nuclear 
corepressor NCoR, an essential part of the HDAC3 deacetylase complex, exhibit 
metabolic and transcriptional effects resembling those of mice without hepatic HDAC3, 
demonstrating that interactions with NCoR are essential for the deacetylase-independent 
function of HDAC344. Additionally, expression of HDAC1 and HDAC3 correlate with both 
estrogen and progesterone receptor expression and have been proposed as potential 
prognostic markers in breast cancer tumors35. 
 HDAC8 is the best biochemically characterized HDAC isozyme to date18,19,45,46. 
HDAC8 is the only class I isozyme that is localized to both the cytoplasm and the nucleus 
and that is not observed in large, multiprotein complexes in vivo47. HDAC8 is 
overexpressed in childhood neuroblastoma48 and T-cell lymphoma25. Knockouts of 
HDAC8 produce skull morphology and growth complications in mice models13 and stop 
cell proliferation in lung, colon and cervical cancer cell lines48. Point mutations in HDAC8 
have been discovered in child patients with symptoms similar to the Cornelia de Lange 
Syndrome (CdLS). Lack of deacetylation of SMC3 in the cohesin complex has been 
implicated as a contributor to this disease, inhibiting the cell cycle, disrupting proper 
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chromatid separation and causing debilitating mental and physical abnormalities9.. 
Knockouts and inhibition of HDAC8 using HDACis have been shown to induce apoptosis 
in T-cell lymphoma and leukemia cell lines25. Using mice xenograft models of oncogene-
amplified neuroblastoma, Rettig et al. demonstrated that selective inhibition of HDAC8 
produces antineuroblastoma activity without significant toxicity and induces cell cycle 
arrest and differentiation both in vivo and in vitro49. Additionally, the combined treatment 
of HDACi and retinoic acid enhanced cell differentiation, demonstrating that inhibition of 
HDAC isozymes can be combined with differentiation-inducing agents to target tumors49.  
Currently, work on HDAC8 has focused on mass spectrometry and 
coimmunoprecipitation studies using the HDAC8 specific inhibitor PCI-34051, which have 
provided insight into potential protein substrates and interaction partners30,50. Recently, 
insight into the substrate selectivity and protein interaction partners have been gained by 
immunoprecipitation and treatment with an HDAC8 specific inhibitor followed by mass 
spectrometry50. However, the full spectrum of substrates have not been identified. 
Investigations of HDAC8 specificity are poised to provide additional insight into the 
biological function and protein-protein interactions of metal-dependent deacetylases. 
Class II HDACs 
 Class II HDACs were discovered in the early 2000s51,52. These proteins are 
significantly larger than both class I and class IV HDACs due to N-terminal and C-terminal 
tails and domains attached to their canonical deacetylase domain. This class is 
subdivided into two subfamilies: Class IIa and IIb. Class IIa consists of HDAC 4, 5, 7, and 
9, and class IIb is comprised of HDAC 6 and 10. These isozymes differ from class I 
HDACs in that the additional N-terminal domains interact with transcription factors to 
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target certain genes, such as the MEF2 proteins, a family of transcription factors that are 
key regulators in cellular differentiation53. Recruitment of class II HDACs by MEF2 
proteins to various protein complexes can alter the protein acetylation landscape due to 
blocking interactions with acetylation complexes such as CREBBP/EP300 in non-
Hodgkin’s lymphoma54,55. Class II HDACs are localized to both the cytoplasm and the 
nucleus. Additionally, both upregulation and downregulation of these isozymes can have 
severe repercussions in various cancers. 
Class IV HDACs 
 HDAC11, the most recently discovered isozyme, is the sole member of the class 
IV HDAC subfamily22. At 39 kDa, HDAC11 is the smallest isozyme. Sequence alignments 
suggest that HDAC11 is more closely aligned with class I HDACs (up to 28% sequence 
identity to HDAC8) than class II, with retention of highly conserved metal binding sites 
seen in other metal-dependent deacetylases. HDAC11 sequence alignments identify one 
significant sequence change, an aspartate (D101 in HDAC8) to asparagine, located in 
the flexible L2 loop, near the entrance to the active site tunnel56. 
 HDAC11 expression is tissue specific, with the greatest expression occurring in 
the brain, heart, kidneys, skeletal muscle and testis22. Studies of murine brain 
development suggest a role for HDAC11 in the formation of mature oligodendrocytes57. 
Overexpression of HDAC11 in RAW264.7 cells is associated with a decrease in mRNA 
levels of the anti-inflammatory cytokine interleukin-10, indicating a possible role for 
HDAC11 in inflammatory and autoimmune diseases58. Furthermore, mRNA analysis 
uncovered a link between HDAC11 and cancer; mRNA levels for HDAC11 are in the top 
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1% of differentially overexpressed genes in ductal breast carcinoma when compared to 
healthy breast tissue59. Finally, the DNA replication factor Cdt1 is a potential HDAC11 
substrate. Cdt1 is integral in recruiting mini-chromosome maintenance (MCM) helicase 
to DNA, which is required for DNA replication during the cell cycle. To maintain a single 
copy of DNA per cell, Cdt1 must be inhibited after loading MCM in the G1 phase60. 
Additionally, Cdt1 is an acetylated protein that coimmunoprecipitates with HDAC1160. 
Finally, HDAC11 knockout mice are viable, but they exhibit increased cell proliferation 
and secrete higher levels of IL-2, TNF and IFN-γ than wild type mice61. 
Mechanism and Inhibition of Metal-Dependent HDACs 
 All metal-dependent HDACs share a common deacetylase domain (Figure 1.3)62. 
Particularly, they possess a conserved pair of histidine residues along with a tyrosine 
deep within the active site tunnel, which are critical for activation and stabilization of the 
metal-water nucleophile and overall catalysis46,63.  
 At the bottom of the HDAC active site tunnel, a divalent metal ion is coordinated 
by an Asp-Asp-His triad in a pentacoordinate, square pyramidal conformation along with 
a water molecule46,63. In crystal structures, the identity of the divalent metal ion is zinc; 
however, multiple divalent metals have been observed to activate HDAC8 catalysis in 
vitro, raising the question of the identity of the divalent metal in vivo45. Our work presents 
an extensive comparison of the reactivity of Fe2+ and Zn2+-HDAC8 with various 
biologically relevant peptide substrates to gain insight into the identity of the in vivo 
divalent metal. 
 Mechanistic studies of HDAC8 have led to a proposed general acid/general base 
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catalytic mechanism (Figure 1.2)18. Upon binding to HDAC8, the carbonyl oxygen of the 
acetyl lysine moiety coordinates the active site metal ion. The metal-water is activated by 
His143 functioning as a general base to attack the carbonyl carbon of the acetyl moiety 
to form a tetrahedral oxyanion intermediate. This intermediate is stabilized through 
interactions with a conserved tyrosine (Tyr306), the divalent metal ion and a protonated 
His142. In a second step, the protonated His143 acts as a general acid, protonating the 
nitrogen of the lysine leaving group to facilitate break down of the tetrahedral intermediate 
to form acetate and lysine products18. 
Most HDAC inhibitors coordinate the divalent metal ion. Although an effective 
strategy, severe side effects have limited their use in the clinic. Three of the FDA-
approved pan-HDAC inhibitors possess a hydroxamic acid (Vorinostat, Panobinostat and 
Belinostat) (Figure 1.4A – for Vorinostat) which has been demonstrated to chelate the 
active site divalent metal ion and target all metal-dependent HDACs. Thus, the need for 
isozyme-specific inhibitors has risen.  
 One isozyme-specific inhibitor has been developed for HDAC8 (PCI-34051) 
(Figure 1.5B). It has a Ki  of 10 nM for HDAC8, and it is at least 200-fold more selective 
towards inhibition of HDAC8 compared to other HDACs25, this inhibitor has proven to be 










Figure 1.4: Hydroxamic acid inhibitors of metal dependent HDACs 
A. The pan-HDAC inhibitor Vorinostat is a hydroxamic acid metal chelator, with a linker and a 
capping group. It is widely used in both research and as a drug to treat T-cell lymphoma. 
B. The HDAC8 specific inhibitor PCI 34051. It has high specificity for inhibition of HDAC8 when 
compared to any other metal dependent HDAC8. It has been used to discover new HDAC8 
substrates 
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Biological Significance of HDAC8 
 Despite the large array of current in vitro characterization, uncovering the biological 
role of HDAC8 in vivo has proven to be challenging. HDAC8 has been shown to be 
involved in a variety of diseases, from cancer to developmental disorders. In vivo, HDAC8 
knockouts in mice have been shown to cause developmental issues due to alterations in 
skull morphology, followed by death64. 
Despite these observations, non-histone HDAC8 substrates remain as elusive 
targets. Current efforts have identified a small array of potential protein substrates using 
co-immunoprecipitation using HDAC-EGFP fusion proteins, stable isotope labeling of 
amino acids in cell culture (SILAC), followed by HDAC inhibitor dosing30,50. These studies 
have provided a snapshot of the versatility of roles that HDAC8 might play in vivo, as well 
as additional avenues to pursue for identifying new HDAC8 substrates. The work 
presented in this thesis presents an alternative, non-invasive system for identifying 
HDAC8-substrate interactions in cell lysates. This method could potentially be adapted to 
identify short-lived interacting substrates of other HDACs. 
Potential in vivo HDAC8 Substrates 
 Current proposed substrates of HDAC8 include the estrogen-related receptor 
alpha (ERRα)65, cAMP response binding protein (CREB)66, AT-rich interactive domain-
containing protein 1A (ARID1A)50, cysteine-rich protein 2-binding protein (CSRP2BP)50, 
and the structural maintenance of chromosomes 3 (SMC3)9,50, among others. 
 Among the proposed substrates, the best characterized HDAC8-substrate is 
SMC3, a core component of the cohesin complex responsible for the proper separation 
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of sister chromatids during cell division67. SMC3 is acetylated during S phase and is 
promptly deacetylated during anaphase, after sister chromatid separation occurs as part 
of a checkpoint process (Figure 1.5)67. Studies have shown that HDAC8 is the 
deacetylase responsible for the deacetylation of SMC3 during  anaphase9. Aberrant 
deacetylation due to SMC3 and/or HDAC8 mutations have been linked to approximately 






Figure 1.5: Regulation of the cohesin complex by HDAC8-mediated 
deacetylation of SMC3 
Figure adapted from 67. HDAC8-catalyzed deacetylation serves as a checkpoint for reassembly of the 
cohesin complex. A separase recognizes deacetylation of SMC3 and removes the RAD21 proteins 
from SMC1A and SMC3 followed by dissociation of the complex. 
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CdLS is a rare genetic disorder characterized by physical deformities and mental 
impairment. Multiple point mutations of HDAC8 have been discovered in infant CdLS 
patients since 201268. Many of these mutations have been expressed in E. coli, with 
crystallographic studies (P91L, A188T, H180R, I243N, T311M, H334R, G320R, among 
others) and basic chemical characterization through circular dichroism of some mutants 
(H180R and G304R).68 Additionally, many of these mutants displayed a noticeable 
decrease in HDAC8-catalyzed deacetylation using a commercially available 
methylcoumarin-bound substrate68. Finally, our laboratory has demonstrated that HDAC8 
catalyzes deacetylation of an SMC3 peptide in vitro50. This thesis further explores  
changes in HDAC8-catalyzed deacetylation cause by each of these mutations. 
Conclusions 
 Lysine acetylation/deacetylation is a dynamic, reversible post-translational 
modification with a defined role in histone modification and a growing pool of non-histone 
substrates that are critical for epigenetic regulation, DNA repair, cell cycle regulation and 
cancer growth and proliferation. The HDAC family of enzymes catalyzes deacetylation of 
both histone and non-histone proteins to maintain acetylation homeostasis that is critical 
for cell regulation and survival. Changes in acetylation patterns have become a key 
feature of various types of cancer and many of these acetylation level changes are due 
to increased expression and/or misregulation of HDACs. Due to the link between HDACs 
and cancer prognosis and survival, these enzymes have become an attractive target for 
drug development, as shown by the development and FDA-approval of pan-HDAC 
inhibitors and current development of novel immune-and oncolytic virus therapies. To 
further our understanding of the cellular function of HDACs, huge strides are currently 
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being made in discovering HDAC specific binding partners and substrates using a variety 
of methods, from gene knockouts and mass spectrometric-proteomic techniques to in 
vivo mammalian cell work. The current body of literature on HDACs has shed light on the 
multiple roles these enzymes perform in both transcriptional regulation and in protein-
protein interactions, particularly with respect to their roles in disease, including multiple 
cancers, developmental disorders, and many others. 
 We predict that future work will incorporate varied approaches, such as mass 
spectrometry, co-immunoprecipitation, in vivo perturbation, in vitro functional studies, 
etc., to advance our understanding of the cellular role of each isozyme. Understanding 
the specificity of each HDAC will provide further insight into their individual roles in the 
regulation of cellular pathways and various other disease states. 
 This thesis outlines the following investigations: an alternative method for 
identifying HDAC8 substrates in cell lysates using non-natural amino acid photo 
crosslinking and validation of these new substrates. An in vitro kinetic evaluation of 
HDAC8 point mutations found in the Cornelia de Lange Spectrum disorders and their 
effect on deacetylation, and the evaluation of HDAC8-catalyzed deacetylation using 
various divalent metal ions in order to determine the metal-dependent substrate specificity 
of HDAC8. Overall, the work presented in this thesis will provide insight into the substrate 
pool, regulation and role of HDAC8 in the cell. 
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Chapter 2 
Identification of Novel HDAC8 Substrates Using Chemical Covalent Capture‡,§ 
Overview 
Lysine acetylation is a reversible, dynamic post-translational modification that has 
been observed in a variety of processes such as chromatin remodeling1, protein-protein 
interactions, protein stability and protein-DNA interactions, among others2.There are two 
families of enzymes that regulate this reversible reaction: the lysine acetyltransferases 
(KATs), which are responsible for catalyzing the addition of the acetyl group from acetyl-
CoA and the histone deacetylases (HDACs), which catalyze removal of the acetyl group. 
The HDAC family is divided into two groups: NAD-dependent sirtuins (class III) and metal-
dependent deacetylases. Metal-dependent deacetylases can be further categorized into 
three subclasses: Class I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 6, 7, 9, and 10) 
and class IV (HDAC 11) based on their sequence homology to yeast orthologs3. 
Acetylation was first observed in histone tails1. However, recent experimental and 
computational studies have demonstrated that acetylation also occurs on non-histone 
                                                          
‡ Reproduce, in part, from a manuscript in preparation: Lopez, J. E.; Haynes, S.; Majmudar, J.D.; Martin, B. 
R.; Fierke, C. A., Identification of novel HDAC8 substrates using Chemical Covalent Capture. In 
preparation. 
§ Jeffrey E. Lopez performed the HDAC8 mutant purifications, incorporation verification, activity testing, 
covalent capture assays, western blotting, proteomics stringency analysis, and full Michaelis-Menten 
kinetics of selected peptides screened and analyzed all the data. Sarah Haynes performed optimized 
proteomics analysis for each HDAC8 mutant. Jaimeen Majmudar performed and optimized the initial 
screens for proteomic analysis. Jeffrey E. Lopez, Sarah E. Haynes, Jaimeen D. Majmudar, Brent R. Martin 
and Carol A. Fierke designed the experiments and analyzed the data. Jeffrey E. Lopez, Sarah Haynes, 
Brent R. Martin, and Carol A. Fierke wrote the manuscript.  
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proteins4, and identification of endogenous HDAC substrates is an important goal in the 
HDAC field.  
Recent efforts have profiled the metal-dependent HDAC interactome via affinity 
purification proteomics, particularly using HDAC-eGFP fusion proteins combined with 
information on potential localization5. These data provide insight into stable protein-
protein interactions of HDAC isozymes, either via direct contact or in a complex. However, 
they likely do not provide an accurate depiction of transient HDAC interactions and the 
fusion protein may potentially hinder interactions with larger binding partners and 
substrates5. Therefore, traditional immunoprecipitation methods have proven insufficient 
for the characterization of the complete cohort of native HDAC substrates. Since 
acetylation is a highly regulated and dynamic process, it is likely that many HDAC-
substrate interactions are transient in nature and thus, there is a need to develop methods 
capable of capturing these HDAC-substrate interactions. Ideally, newly developed 
methods should require a small surface area to capture interactions while simultaneously 
being compatible with current mass spectrometry and proteomic approaches.  
HDAC8, the best structurally characterized isozyme of the class I subfamily of 
deacetylases6–8 and has been crystallized with a wide variety of ligands and peptides, yet 
the substrate pool for this isozyme remains largely unknown9. This makes HDAC8 an 
ideal enzyme for developing new methods for HDAC-substrate identification. To date, 
only two HDAC8 substrates had been identified and validated in vivo: estrogen-related 
receptor alpha (ERR-α), and the structural maintenance of chromosomes 3 (SMC3). 
ERR-α was identified as an HDAC8 substrate through in vivo co-transfection and in vitro 
radiolabeling and deacetylation assays10. SMC3 is part of the cohesin complex 
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responsible for the separation of sister chromatids in the cell, and it was identified as an 
HDAC8 substrate through the discovery that HDAC8 missense mutations and lack of 
SMC3 deacetylation are correlated in clinical patients. These mutations have been 
implicated in various phenotypes related to the Cornelia de Lange Spectrum disorders 
and has become the best validated in vivo HDAC8 substrate to date11–13. Finally, a recent 
SILAC study discovered several putative substrates using an HDAC8-specific inhibitor, 
namely AT-rich interactive domain-containing protein 1A (ARID1A), cysteine-rich 
protein2-binding protein (CSRP2BP), nuclear receptor coactivator 3 (NCOA3), among 
others14. 
Here, we report an alternative method for the identification of potential HDAC8 
substrates using chemical covalent capture, where the photoreactive non-natural amino 
acid p-benzoyl-l-phenylalanine (Bpa) is used to capture protein-protein interactions, 
which are then analyzed using mass spectrometry. Non-natural amino acid incorporation 
has shown to efficiently trap protein-protein interactions with transcriptional activators in 
vivo15.  We demonstrate that this approach also successfully captured transient HDAC8-
protein interactions, identifying more than 100 proteins that interact with HDAC8. The 
majority of these proteins have been previously identified as being acetylated in vivo.  We 
validated reactivity with HDAC8 of several of these potential substrates using small 
acetylated peptide mimics with an acetate coupled assay16. We demonstrated that these 
peptides possess catalytic activity higher than those measured for a peptide substrate 
based on an acetylated lysine on SMC3 (SMC3 K106), the best validated HDAC8 
substrate.  
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Materials and Methods 
Materials. 
Unless specified, chemicals and supplies were purchased from Fisher or Sigma. 
All chemicals were purchased at the highest quality available. Chromatography resins 
were purchased from GE Healthcare. 
Expression of HDAC8-Bpa Mutants 
Site-directed mutagenesis for amber codon incorporations (TAG) for Y100 (TAT), 
I94 (AAT) and F191 (TTT) of the pHD2-TEV-His HDAC8 plasmid were conducted using 
a QuikChange kit (Stratagene)7. Incorporation of desired mutations was confirmed by 
DNA sequencing (University of Michigan Sequencing Core). For incorporation of the non-
natural amino acid, p-benzoyl-l-phenylalanine, into HDAC8, a vector (pEVOL) containing 
evolved Methanocaldococcus jannaschii aminoacyl-tRNA synthetases/suppressor tRNA 
pairs was purchased from AddGene17. Recombinant HDAC8-Bpa variants at positions 
Y100, I94 or F191 were expressed in BL21(DE3) Escherichia coli cells according to a 
previously published procedure7, with small modifications. Briefly, cells were plated on LB 
media plates with 100 μg/mL ampicillin and 34 μg/mL chloramphenicol.  Then a single 
colony was used to inoculate 50 mL cultures (2xYT media supplemented with 100 μg/mL 
ampicillin and 34 μg/mL chloramphenicol) that were grown overnight.  These cultures 
were used to inoculate 4 liters of media per each mutant (2xYT media supplemented with 
100 μg/mL ampicillin and 34 μg/mL chloramphenicol). Cells were grown at 37ᵒC until 
OD600 reached 0.4 - 0.6, at which point the temperature was lowered to 20ᵒC.  After 1 
hour, cells were induced by the addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside 
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(IPTG), 0.2% w/v L-arabinose and 200 μM ZnSO4, and grown overnight at 20ᵒC. Cells 
were harvested by centrifugation (4000 x g, 15 min, 4ᵒC). The cells were resuspended in 
buffer A (30 mM HEPES pH 8.0, 150 mM NaCl, 1 mM imidazole, 1 mM TCEP and 5 mM 
KCl with 1 protease inhibitor cocktail tablet per 50 mL of buffer (Roche Diagnostics)).  
Purification of HDAC8-Bpa Variants. 
Cells were lysed using a microfluidizer (Microfluidics) followed by centrifugation 
(27,000 x g, 45 min, 4ᵒC). The cleared lysate was applied to NiSO4-charged immobilized 
Sepharose fast flow metal affinity column and then eluted with a gradient of increasing 
imidazole concentration (25 - 200 mM imidazole in 30 mM HEPES pH 8.0, 150 mM NaCl. 
1 mM TCEP and 5 mM KCl). HDAC8-Bpa mutants were then dialyzed overnight at 4ᵒC 
against 25 mM MOPS pH 7.5, 1 mM EDTA, 1 mM TCEP and 5 mM KCl to remove any 
trace metals and then dialyzed again overnight at 4ᵒC against 25 mM MOPS, pH 7.5, 1 
mM TCEP and 5 mM KCl to ensure complete trace metal removal. HDAC8-Bpa mutants 
were concentrated to 150 - 300 μM and stored at -80ᵒC.  Bpa incorporation was verified 
by mass spectrometric analysis using an Agilent Q-TOF (Time-Of-Flight) HPLC-MS 
(University of Michigan) 
Enzyme Activity Assay. 
Before assaying, zinc was bound to the enzyme by incubation of apo-HDAC8-Bpa 
(10 μM) with atomic absorption zinc standard (Fluka) at a stoichiometric ratio on ice for 1 
hour prior to dilution into the assay. The catalytic activity of HDAC8-Bpa variants was 
measured using the Fluor-de-Lys tetrapeptide assay substrate Ac-Arg-His-Lys(ac)-
Lys(ac)-aminomethylcoumarin (Enzo Life Sciences). Deacetylation of the substrate by 
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HDAC8 is followed by the cleavage of the amide bond linking the C-terminal 
aminomethylcoumarin to the peptide backbone by a protease developer, resulting in a 
fluorescence shift. Activity assays were run at 30ᵒC in assay buffer (25 mM HEPES pH 
7.8, 137 mM NaCl, 3 mM KCl) that contained 100 μM peptide with 1 μM HDAC8-Bpa 
variant. The ratio of product fluorescence (ex. = 340 nm, em. = 450 nm) divided by the 
substrate fluorescence (ex. = 340 nm, em. = 380 nm) increases with product 
concentration. The initial rate was determined using the ratio of product formed over time. 
The catalytic efficiency (kcat/KM,app) was determined from dividing the initial rate by enzyme 
concentration.   
Cell Culture and Treatment. 
HEK293 cells (ATCC) were grown, expanded in DMEM medium from the same 
frozen vial stock and adhere into 75 cm2 flasks in DMEM medium (~ 6 million cell/plate, 
10 mL per plate). Prior to crosslinking, cells were detached by incubation with 0.05% 
Trypsin followed by neutralization with DMEM medium.  The cells were sonicated (1-3 
minutes, 10% duty cycle), centrifuged (17000 x g, 25 minutes) resuspended in 1 mL of 
phosphate buffer saline (PBS), aliquoted and stored at -80 ᵒC. 
Conjugation of Magnetic Beads. 
Pierce™ Anti-6xHIS Epitope tag monoclonal antibodies (Thermo Scientific) (100 
μg/mL) were coupled to M-270 epoxy Dynabeads (Invitrogen) using an optimized version 
of the suggested protocol. Briefly, magnetic beads (5 mg/pulldown) were washed twice 
with 1 mL of 0.1 M sodium phosphate buffer (pH 7.4) for a period of 10 minutes between 
washes. The buffer was removed and the beads resuspended with anti-6xHIS antibody 
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(100 μg of antibody/5 mg of beads) followed by addition of 0.1 M sodium phosphate buffer 
to bring the volume to 200 μL. After mixing, 100 μL of 3 M ammonium sulfate were added 
to bring the total volume to 300 μL. The beads were then incubated for 16-24 hours at 
37ᵒC. Finally, beads were washed with PBS prior to addition of the crosslinking samples. 
HDAC8 Chemical Covalent Capture Assay. 
HDAC8-Bpa variants were thawed and diluted in PBS (pH 7.4) to a concentration 
of 40 μM and kept on ice. 10 aliquots of HEK293 cells were thawed, resuspended and 
lysed in 800 µL of PBS using sonication and lysates were centrifuged (27,000 x g, 15 
minutes, 4ᵒC) to remove insoluble material. Cell lysate protein concentrations were 
measured using a bicinchoninic acid (BCA) protein assay (Thermo-Scientific)18. HDAC8-
Bpa variant was mixed with HEK293 lysate to a final volume of 140 μL (HDAC8-Bpa = [5 
μM]). Samples were incubated at 4ᵒC for 15 minutes and then either irradiated using an 
ultraviolet light lamp (Thermo Scientific) at a wavelength of 365 nm (115 volts, 60 Hz) for 
20-30 minutes or kept in the dark for the non-UV control samples. The crosslinked and 
non-crosslinked samples were then added to the beads and incubated for 1-2 hours with 
rotation at 4ᵒC.  
Western Blotting. 
Samples from HEK293 lysates, UV-crosslinking assays and elutions from the 
Dynabeads were collected. Gel electrophoresis was performed using Mini-PROTEAN 
TGX 12% gels (Bio-Rad). Proteins were transferred to a nitrocellulose membrane and 
probed using anti-6xHIS epitome tag monoclonal antibodies (Fisher) and a mouse anti-
HDAC8 monoclonal antibodies (Santa Cruz Biotech). The membrane was then probed 
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with either a secondary HRP-linked antibody and chemiluminescence induced by 
subsequent incubation with a HRP substrate (Santa Cruz Biotech) for the anti-6xHIS 
epitome tag antibody or by an anti-mouse Alexa Fluor® 633 antibody (Innovagen). 
Visualization was done using a C600 Series imager (Azure Biosystems) and visualized 
using ImageJ (NIH). 
Proteomics. 
Beads containing both HDAC8-Bpa crosslinked and non-crosslinked samples 
were washed twice with ice-cold PBS (pH 7.4) and resuspended in ice-cold 6 M urea. 
Protein samples were incubated with 10 mM dithiothreitol for 30 minutes at 37 ᵒC followed 
by alkylation using 55 mM iodoacetamide for 30 minutes at 25ᵒC in the dark. Samples 
were diluted to 1 M urea using PBS and digested overnight by incubation with 
sequencing-grade Trypsin/Lys-C (Promega). Peptide samples were desalted using Oasis 
HLB Prime µElution C18 solid-phase extraction cartridges (Waters) following the 
manufacturer’s protocol. Desalted peptides were reconstituted in water with 3% 
acetonitrile, 0.1% formic acid and 10 fmol/μL yeast alcohol dehydrogenase digest 
(Waters) as an internal standard. In triplicate, peptides were analyzed in positive mode 
on a Synapt G2-S HDMS traveling wave ion mobility time-of-flight (TOF) mass 
spectrometer (Waters). Reversed-phase liquid chromatography and data-independent 
acquisition were performed as previously described19. Peptide identification and label-
free protein quantitation were performed with Progenesis QI for Proteomics 2.0.5 
(Nonlinear Dynamics) against a database of the human proteome (downloaded from 
UniProt on February 2, 2016). Peptide and protein identifications were made using the 
following criteria:  tryptic cleavage rules with one missed cleavage allowed, 
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carbamidomethyl cysteine as a fixed modification and methionine oxidation as a variable 
modification, a minimum of two identified fragment ions per peptide and a minimum of 
five fragments per protein, and at least two identified peptides per protein. The global 
false discovery rate (FDR) for protein identification was set at 1% using a reversed 
database. Peptide identifications with a calculated mass error greater than 10 ppm were 
not considered. Fold-change, p-value (equation 2.1) and number of unique peptides were 
used to rank the confidence of hits. 










              (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2.1) 
Peptide Identification and Screening of Acetyl Lysine Positions. 
Proteins identified through peptide fragments were screened for potential 
acetylated lysine positions using PhosphoSite Plus. These acetylated lysine positions 
were then evaluated using the Rosetta Flex-Pep-Bind structure-based protocol tailored 
to HDAC820. Acetylated lysine residues with the highest overall algorithm score were 
considered as the best candidates for in vitro peptide testing. A library of 58 peptides  
based on identified proteins from all of the HDAC8-Bpa mutant crosslink experiments was 
purchased. Peptides varied in length to enhance water solubility using a peptide solubility 
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HDAC8-Peptide Activity. 
Desalted peptides (>75% purity) were purchased from Synthetic Biomolecules with 
an acetylated N-terminus, an amidated C-terminus and a single acetylated lysine. 
Peptides were resuspended in water unless otherwise specified. Peptide concentrations 
were measured using a micro-bicinchoninic acid (micro-BCA) protein assay (Thermo-
Scientific). Recombinant wild-type HDAC8 was purified from E. coli7. HDAC8 assays were 
performed using an enzyme-coupled assay to measure acetate production16. Reactions 
were performed using a standard HDAC reaction buffer (25 mM HEPES pH 7.8, 137 mM 
NaCl, 3 mM KCl at 30ᵒC). Reactions measuring deacetylation of acetylated peptides (12.5 
- 100 μM) were initiated by the addition of recombinant Zn(II)-HDAC8 (1 μM). The 
reactions were quenched with 10% HCl, and the acetate product, as reflected by an 
increase in NADH fluorescence, was measured at 5 time points (up to 50 min) and used 
to calculate the initial rates. Steady state kinetic parameters (kcat, KM, and kcat/KM) were 
calculated by fitting either the Michaelis-Menten equation or a line, where deemed 
appropriate, to the substrate concentration dependence of the initial rate.  
Results and Discussion 
Site-directed incorporation of Bpa identifies a variety of HDAC8 interactions. 
 To facilitate covalent capture, incorporation of a non-natural amino acid photo-
crosslinker was carried out using amber stop codon nonsense suppression in E. coli17. 
To trap interactions based on protein proximity, all mutations were designed such that the 
incorporated Bpa is expected to be solvent and surface exposed. Furthermore, positions 
for incorporation were chosen based on their distance to the active site, and preliminary 
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data of using covalent capture with Rpd3, the yeast ortholog of HDAC822. Ultimately, Bpa 
was incorporated at three positions: Y100, I94 and F191 (Figure 2.1A).  Substitutions of 
Bpa at these three sites decreased values of kcat/KM for deacetylation of the Fluor-de-
Lys coumarin-labeled tetrapeptide by values of 2-fold (Y100) to 7-fold (I94) 
 
Figure 2.1: HDAC8 Bpa mutations 
(A) Incorporation positions of Bpa on HDAC8. Positions were chosen based on proximity to the 
tethered peptide that is bound. (B) Y100 - this residue substitution is in close proximity to the active 
site binding surface and appears to interact with the bound peptide. (C) I94 - this residue substitution 
is located in the L2 loop, a region hypothesized to aid in the binding of peptide substrate to the active 
site surface. (D) F191 - this residue substitution is located 20 ᵒA away from the active site metal and 






  38 
Specifically, Y100 was selected as a site for Bpa incorporation to capture 
substrates due to:  an immediate proximity to the active site tunnel with potential 
interactions with the methylcoumarin moiety (Figure 2.1B). The methylcoumarin-HDAC 
interaction has demonstrated a modest effect of enhancement on overall catalytic 
turnover6 consistent with our measurements of the activity of the Y100Bpa variant. 
Crosslinking with I94 was of interest because it is positioned on the L2 loop of HDAC8, a 
primarily disordered loop in the crystal structures HDAC8•peptide complexes which has 
been proposed to aid in substrate binding and release6,9,23,24 (Figure 2.1C). This 
substitution had the largest effect on catalytic activity. Finally, F191 is located 24 Aᵒ away 
from the active site tunnel (Figure 2.1D). This position was selected as a control to try to 
distinguish between protein substrates and protein interaction partners. Identification of 
proteins that interact with HDAC8 at sites other than the active site will provide insight 
into protein binding partners that could affect HDAC8 function and specificity. 
Incorporation of Bpa at these three, independent positions resulted in the covalent 
capture of previously unidentified protein substrates that provide insight into the HDAC8 
protein substrate pool and the role of HDAC8 in cellular homeostasis. 
For the covalent capture experiments, HDAC8-Bpa variants were incubated with 
HEK293 lysate, irradiated using an ultraviolet light lamp (+UV samples), 
immunoprecipitated, proteolyzed and the crosslinked proteins identified by LC-MS/MS 
analysis of peptides (Figure 2.2). Control samples were prepared identically without 
irradiation (-UV samples).   
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We verified covalent capture for each mutant by western blot (Figure 2.3). We used 
a mouse anti-HDAC8 monoclonal antibody as a primary antibody (Santa Cruz Biotech) 
followed by an anti-mouse Alexa Fluor® 633 antibody (Innovagen). We saw that irradiated 
samples possess multiple, heavier molecular weight bands above the recombinant 
HDAC8-Bpa bands, indicating the covalent capture of higher molecular weight proteins. 
The resulting data set led to identification of a large number of unique proteins (Table 2.2 
and Figure 2.5). HDAC8 with a Bpa substitution at Y100 captured the largest number of 
different proteins (452), likely due to the proximity to the active site tunnel. Fewer proteins 
were identified for the I94Bpa variant (123), possibly due to the decreased catalytic 
activity.  Finally, the F191Bpa variant yielded the fewest number of unique proteins 
captured (45) out of all three variants, suggesting both that less proteins interact with this 
region of HDAC8. 
 Figure 2.2: Scheme of Chemical Covalent Capture using HDAC8. 
Recombinant HDAC8-Bpa mutants were added to HEK293 lysate and incubated on ice. Potential 
HDAC8-substrate interactions were covalently captured by activating Bpa using UV light. Conjugation 
to an α-6HIS antibody coupled to magnetic beads was done immediately post-covalent capture. Co-
immunoprecipitation and verification via Western Blots were done simultaneously, followed by mass 
spectrometry and proteomic analysis in order to identify new HDAC8 substrates. 
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The resulting data sets for -UV (N = 3 biological replicates) and +UV (N = 3 
biological replicates) samples were compiled and the identified proteins for each HDAC8-
Bpa variant were subject to stringent cutoffs per the following criteria (Figure 2.4): (i) 
proteins showed an overall fold enrichment (+UV/-UV) of ≥ 2.5-fold for; (ii) a t-test 
between UV and non-UV treated data sets for each protein generated a p-value of ≤ 0.05; 
and (iii) at least two peptide fragments per protein were identified. These stringency 
cutoffs significantly reduce (by 3- to 22-fold) the number of specific HDAC8-protein 
interactions identified for all three mutants, with the largest differential being the p-value 
score.  Furthermore, the increased stringency severely reduced the number of proteins 
identified that crosslinked to more than one of the Bpa variants,  suggesting that some of 
Figure 2.3: HDAC8-Bpa covalent capture western blot 
Western blot of recombinant HDAC8-Bpa mutants with HEK293 lysate after UV exposure. The 
membrane was blotted with an anti-HDAC8 monoclonal antibody and an anti-mouse Alexa Fluor® 633 
secondary antibody. We observed higher molecular weight bands in UV exposed samples, suggesting 
that covalent capture occurred in these samples. Western blots were performed in triplicate. 
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the initially identified proteins in these categories made nonspecific interactions.   It is 
possible that some protein substrates that have long-lived, stable interactions with 
HDAC8, such as those identified in previous proteomic studies5,14, were deleted using 
these cutoffs if they are abundant in both +UV and -UV samples.  In particular, two 
substrates that form stable complexes with HDAC8, namely ERR-α and SMC3, were 
identified in the original pool of proteins for the Y100Bpa variant but were removed by the 
cutoffs as the +UV/-UV ratio was not larger than 2.5.  
These criteria identified new potential protein substrates based on their capture 
efficiency, statistical fidelity and enrichment.  The Y100Bpa exhibited the highest number 
of proteins after undergoing stringent cutoffs, and ≥ 90% of proteins captured by this 
mutant exhibit multiple acetylation sites based on the Phosphosite Plus database.  These 
results suggest that the proteins that formed crosslinks with Y100Bpa are likely 
substrates. This covalent capture proteomics reveal a vast network of previously identified 
interacting proteins of HDAC8 as well as a large subset of newly identified interacting 










Figure 2.4: Evaluation and stringency cutoffs of HDAC8 Chemical Covalent 
Capture 
(A) Total enrichment of proteins covalently captured with each HDAC8-Bpa mutants along with common 
proteins between all mutants. (B-D) Volcano plots of Y100Bpa, I94Bpa and F191Bpa; each mutant was 
subject to the same stringency cutoffs: fold enrichment (+UV/-UV) ≥ 2.5,  p-value of ≤ 0.05 and a minimum 
of two peptide IDs per protein ID. (E) Enrichment after stringency for each HDAC8-Bpa variant.  The 
Y100Bpa exhibited the highest number of proteins after stringent cutoffs,and ≥ 90% of proteins captured 
by this mutant exhibit multiple acetylation sites based on the Phosphosite Plus database. 
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HDAC8 testing reveals high turnover of novel peptide substrates. 
To further investigate whether the identified proteins are likely HDAC8 substrates 
we measured the reactivity of HDAC8 with peptides containing acetylated lysine residues 
taken from the 135 proteins that remained after applying our stringency cutoffs (Table 
2.1).   
Table 2.1 - Proteins identified through HDAC8 covalent capture after cutoffs 
Protein ID UV/No UV FC p-value (UV/No UV) # peptides ID 
SYAC 24.311 0.024 2 
PGAM4 7.266 0.027 5 
SYEP 5.163 0.016 4 
H14 4.968 0.017 5 
COPA 4.577 0.020 8 
SYQ 4.544 0.022 2 
LARP1 4.254 0.037 4 
PDLI1 4.206 0.031 3 
ACTN2 4.191 0.032 11 
DHX9 4.158 0.024 5 
RL7A 4.131 0.050 10 
ESYT1 4.095 0.036 6 
LPPRC 4.093 0.032 18 
HSP72 4.065 0.027 53 
PSA 4.031 0.039 23 
ITB1 4.025 0.038 7 
CAPR1 4.002 0.033 5 
LRC47 3.976 0.047 2 
MSH2 3.960 0.036 3 
TIF1B 3.939 0.036 21 
CDK1 3.937 0.052 5 
EIF3B 3.929 0.027 7 
VPS35 3.924 0.026 4 
UBA1 3.879 0.036 46 
DPP3 3.779 0.027 9 
RENT1 3.766 0.026 10 
NCAP 3.766 0.044 2 
HS90B 3.758 0.037 87 
SFPQ 3.757 0.035 13 
ACTN1 3.736 0.021 16 
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ENPL 3.724 0.038 51 
KINH 3.713 0.027 19 
C1TC 3.704 0.033 36 
HNRL1 3.702 0.040 2 
RBBP7 3.662 0.045 4 
MCM6 3.649 0.042 10 
PARP1 3.639 0.031 32 
EZRI 3.622 0.030 26 
HS105 3.619 0.033 19 
PSMD2 3.616 0.034 8 
TPIS 3.609 0.026 21 
CLH1 3.597 0.027 45 
ACLY 3.584 0.036 20 
GANAB 3.562 0.031 27 
P5CS 3.556 0.037 11 
EIF3C 3.528 0.045 9 
AT1A1 3.508 0.034 19 
CAND1 3.507 0.026 24 
DDB1 3.484 0.028 5 
CPSF6 3.477 0.021 6 
CSDE1 3.473 0.033 5 
HSPB1 3.462 0.060 3 
1433B 3.456 0.065 10 
IPO7 3.451 0.027 3 
PSD12 3.451 0.020 5 
ACON 3.440 0.048 3 
ACTN4 3.422 0.032 35 
EF2 3.402 0.040 93 
HNRPU 3.396 0.045 22 
COPB2 3.395 0.023 9 
ADH1YEAST 3.382 0.048 59 
TERA 3.380 0.044 34 
HXK1 3.367 0.026 6 
AINX 3.361 0.044 3 
XRCC5 3.359 0.033 20 
STRAP 3.343 0.047 4 
TNPO1 3.340 0.043 8 
SAE2 3.324 0.036 4 
MCM7 3.319 0.030 12 
SND1 3.314 0.042 17 
VINC 3.299 0.034 40 
GLRX3 3.267 0.028 11 
HS90A 3.266 0.037 92 
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GBLP 3.253 0.070 6 
LAP2B 3.252 0.042 8 
MYH9 3.248 0.028 63 
MYH14 3.234 0.044 16 
MCM5 3.201 0.036 11 
VDAC1 3.194 0.029 10 
ACOT9 3.169 0.026 7 
SF01 3.148 0.028 7 
DHX15 3.140 0.041 6 
STX11 3.137 0.029 4 
MIC60 3.129 0.038 8 
IPYR 3.127 0.039 6 
DHE3 3.123 0.032 12 
COPG1 3.104 0.044 8 
AXA2L 3.099 0.052 21 
U5S1 3.070 0.043 18 
PDIP2 3.052 0.029 2 
EF1B 3.050 0.045 2 
NUCL 3.044 0.043 43 
AIP 3.017 0.040 3 
DDX17 3.009 0.040 29 
RIR1 2.996 0.037 10 
FUS 2.954 0.047 5 
PRDX1 2.905 0.040 4 
UBQL1 2.880 0.046 2 
NSUN2 2.868 0.033 9 
FUBP1 2.854 0.035 13 
IMB1 2.852 0.044 25 
PHB2 2.843 0.032 18 
ACTZ 2.804 0.012 5 
ROA1 2.776 0.046 7 
EIF3A 2.740 0.044 24 
STAU1 2.732 0.049 4 
PYGL 2.720 0.044 8 
FETUA 2.701 0.043 8 
SETP9 2.688 0.037 5 
G3PT 2.679 0.000 2 
HSP74 2.672 0.044 22 
PCBP1 2.662 0.035 11 
GDIA 2.633 0.043 11 
SRSF7 2.615 0.030 2 
RL8 2.595 0.048 15 
BACH 2.595 0.035 4 
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ANXA2 2.570 0.040 25 
HS74L 2.547 0.046 10 
LDHC 2.544 0.044 3 
PRS10 2.539 0.027 3 
KCRB 2.504 0.035 15 
TBB2A 2.503 0.040 55 
HUS1B 39.205 0.001 2 
ADT1 10.596 0.002 7 
S10A9 5.431 0.001 5 
TXLNA 5.421 0.002 4 
VDAC1;VDAC3 5.178 0.001 6 
HS71L 3.914 0.007 5 
COX41 3.654 0.032 2 
RL3 3.486 0.003 18 
PHB 2.678 0.040 10 
PLMN 2.664 0.005 5 
ROA1;RA1L2 3.911 0.001 3 
IL6 3.745 0.005 3 
TIAR 2.507 0.000 3 
 
We used the HDAC8 Flex-Pep-Bind algorithm20 to score potential binding and 
activity with each of the acetylated lysine residues identified in Phosphosite Plus database 
for each protein.  We then purchased fifty-eight (58) short, synthetic peptides 
corresponding to the acetylated lysine sites with the highest algorithm score and the 
largest fold change (+UV/-UV ratio). The reactivity of zinc-bound HDAC8 with all water 
soluble potential peptide substrates (38 peptides) was measured using an acetate-
coupled assay16 with at least two concentrations of substrate (50, 100 μM or more) (Table 
2.2). These data reveal that 30% of the peptides tested have values of kcat/KM > 30 M-1s-
1.   
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Table 2.2 - HDAC8 deacetylation screen of protein-based peptide substrates 




Peptide sequence kcat/KM (app) (M-1s-1) 
ACLY 3.95 -20.5 DHKQ(K-Ac)FYWGHK 220 
HSP90AB1 4.15 -20.8 YK(K-Ac)FYE 155 
HSP90AA1 3.59 -20.8 YK(K-Ac)FYE 155 
ITGB1 4.44 -20.1 TL(K-Ac)FKR 70 
PFKP 4.11 -18.3 HRIP(K-Ac)EQW 56 
TUBA1A 5.2 -19.8 DH(K-Ac)FDL 40 
PDLIM1 4.06 -14.6 GG(K-Ac)DFE 33 
LARP1 4.65 -22.2 YV(K-Ac)RRR 33* 
TRIM28 4.35 -17.3 RMF(K-Ac)QFNK 32 
SLC25A4 10.59 -19.4 ET(K-Ac)YRW 30 
UPF1 4.13 -16.3 RYKGDLAPLW(K-Ac)GIGHVIKVPD 30 
COPA 5.05 N/A DY(K-Ac)IKV 23 
AARS 24.31 -17.6 FF(K-Ac)RNE 21* 
SEC24C 4.72 -18.6 MH(K-Ac)EIR 21* 
SFPQ 4.14 -19.5 EF(K-Ac)RLF 18* 
VDAC1 3.43 -18 FF(K-Ac)GAW 17* 
ACTIN1 4.13 -16.9 YG(K-Ac)LRK 17* 
HIST1H1E 5.16 -18.2 AAL(K-ac)KAL 16* 
KIF5B 4.07 -16.8 YE(K-Ac)EKE 16* 
NPEPPS 4.45 -17.2 PE(K-Ac)KRP 15* 
MSH2 4.37 -19.2 RIIL(K-Ac)ASRH 15* 
VPS35 4.34 -15.8 GG(K-Ac)RVM 15* 
EiF3B 4.33 -17.5 GE(K-Ac)FKQ 15* 
CPNE3 3.44 -16.3 FH(K-Ac)QTSD 14* 
QARS 4.54 -17.2 EPEPGF(K-Ac)RLAWGQ 12* 
HSP90B1 4.11 -18.1 SQ(K-Ac)KTF 11* 
MTHFD1 4.08 -15.9 TD(K-Ac)ALFNR 11* 
PARP1 4 -18.6 LS(K-Ac)KSK 11* 
PCBP1 2.66 -15.8 HG(K-Ac)EVG 10* 
RPL3 3.48 -19.3 PL(K-Ac)KDR 8* 
CAPRIN1 4.41 N/A TY(K-Ac)VLK 8* 
DPP3 4.17 N/A AH(K-Ac)RGS 8* 
EPRS 5.69 -18.1 EF(K-Ac)HPQ 7* 
S100A9 5.43 -19.5 AH(K-Ac)KSH 5* 
HSP90A1L 3.91 -18.7 EF(K-Ac)RKH 5* 
HDLBP 7.84 N/A KSQH(K-Ac)YVIPK 3* 
ESYT1 4.51 -16.5 KGT(K-Ac)HLS 3* 
UBA1 4.28 -18.5 VS(K-Ac)RKL 2* 
*only tested as one concentration with HDAC8 
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We then tested the peptides with kcat/KM values higher than 30 M-1s-1 using various 
peptide concentrations. In fact, eight peptides have kcat/KM values for deacetylation of 
acetylated peptides that are comparable to or faster than the values for SMC3-based 
peptides14 (Figure 2.5B) where SMC3 is the best validated in vivo HDAC8 substrate. This 
set included peptides from proteins identified in previous proteomic studies as HDAC8-
specific or pan-HDAC interacting proteins, including heat shock protein 90 
(HSP90AB1)25, tubulin 1-alpha (TUBA1A)26 and transcription intermediary factor beta 
(TRIM28)27. Excitingly, this analysis also validated new putative HDAC8 protein 
substrates such as ATP-citrate lyase (ACLY), integrin beta-1 (ITGB1), 6-
phosphofructokinase (PFKP), PDZ and LIM domain protein 1 (PDLIM1), and the regulator 
of nonsense transcripts (UPF1). The highly reactive peptides from ACLY (240 ± 55 M-1s-
1), ITGB1 (435 ± 150 M-1s-1), UPF1 (350 ± 130 M-1s-1) and PFKP (106 ± 48 M-1s-1) suggest 
that these proteins are particularly interesting to study further as biological substrates of 
HDAC8.  
The HDAC8-catalyzed deacetylation of peptides from proteins previously 
observed in proteomic studies and novel proteins provide evidence that this covalent 
capture approach can be used to identify novel deacetylase targets.  Additionally, the 
Y100 amino acid is conserved in multiple metal-dependent deacetylases (i.e. HDAC6, 
HDAC7 and HDAC10) so that this experiment could be repeated with little optimization 
for these isozymes.  Many of the putative HDAC8 substrates are involved in a wide variety  
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of cellular processes, such as metabolism, cell differentiation and DNA repair suggesting 
that HDAC8 could have different roles depending on its cellular localization (Figure 2.5A).  
 
 
Figure 2.5: Representative putative substrates and peptide testing 
(A) Localization, function and steady state parameters for the deacetylation of synthetic acetylated 
peptides corresponding to a subset of identified HDAC8 substrates. Reactions were catalyzed by Zn2+-
HDAC8. (B) Dependence of Zn2+-HDAC8 catalyzed deacetylation on the concentration of PFKP, UPF1 
and ITGB1 peptides and compared against an SMC3 synthetic peptide. The Michaelis-Menten equation 
is fit to the data. 
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Interestingly, some of these proteins, namely TUBA1A, ITGB1 and PDLIM1 are 
found in both the cytoplasm and bound to the cytoskeleton of the cell.  HDAC8 has been 
visualized bound to the actin cytoskeleton in human smooth muscle cells and along 
siRNA knockouts of HDAC8 that have shown that they can significantly alter the cellular 
cytoskeleton26  and has been hypothesized to regulate actin dynamics and cytoskeleton 
interactions through protein complex formation with HSP20, myosin heavy chain and 
cofilin26, 28, 29. However, neither HSP20 or cofilin have been observed as HDAC8 targets, 
and myosin associates better with HDAC8 in a non-acetylated form, suggesting that it is 
not an HDAC8 substrate29. The covalent capture results suggest that TUBA1A, ITGB1 
and PDLIM1 might be the cytoskeletal targets of HDAC8.  Additionally, our data suggests 
that HSP90 is a putative HDAC8 substrate. HSP90 has been proposed to play a role in 
modulating actin dynamics30,25, thus making it another potential target for HDAC8 in the 
cytoskeleton. Consistent with this, a bacteria two-hybrid experiment indicated that HDAC8 
interacts with  HOP1, an adaptor protein linking HSP70 and HSP9031. 
The covalent capture and peptide reactivity data suggest that HDAC8 activity could 
regulate nonsense-mediated decay of mRNAs by catalyzing deacetylation of UPF1. 
UPF1 is recruited to mRNAs upon translation termination and plays a role in replication-
dependent histone mRNA degradation32,33. Although UPF1 complex formation is 
regulated by phosphorylation, it is possible that HDAC8-catalyzed deacetylation regulates 
UPF1 function at certain times of the cell cycle, as hypothesized with SMC3 during 
mitosis11. 
Unexpectedly, these data suggest that HDAC8 might also act as a potential 
regulator of glycolysis, fatty acid biosynthesis and metabolites that are associated with 
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cancer (oncometabolite). Two of the proteins discovered in our screen, PFKP and ACLY, 
are involved in cell energy production and storage, respectively. PFKP is responsible for 
the first committed step in glycolysis, the phosphorylation of D-fructose 6-phosphate to 
fructose 1,6-bisphosphate while ACLY is responsible for converting citrate to acetyl-CoA, 
linking multiple metabolic and biosynthetic processes34,35. We hypothesize that metal 
dependent HDACs might play a larger role in cellular metabolic regulation than previously 
thought. 
Finally, and consistent with previous in vitro peptide studies24,36, it appears that a 
common motif for HDAC8 catalysis is the presence of aromatic residues, mainly 
phenylalanine and tyrosine, near the acetyllysine. Of the eight peptides with highest 
reactivity, six contain a phenylalanine at the -1 or -2 position.  This motif might increase 
either binding affinity or reactivity, possibly similar to the observed interactions with the -
1 coumarin moiety visualized in the HDAC8-peptide crystal structures23,37,38.  The 
appearance of an aromatic residue downstream of the acetyllysine might be an indication 
of a biological substrate.  
Conclusions 
Overall, we have identified new potential HDAC8 substrates using chemical 
covalent capture coupled with proteomics and in vitro peptide validation. The protein-
based peptides tested possess comparable deacetylation rates to an SMC3 peptide 
mimic, the best in vivo validated HDAC8 protein substrate. These newly identified proteins 
possess a diverse array of both nuclear and cytosolic functions; including cell regulation 
and homeostasis, chromatin and DNA remodeling and cell cytoskeleton regulation; 
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suggesting that HDAC8 might have a role in various cellular processes not investigated 
previously. This alternative approach provides a new strategy that could be useful for the 
identification of other HDAC isozyme substrates and provide a better understanding of 
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Chapter 3 
Effects of Cornelia de Lange Spectrum Mutations on HDAC8 Catalysis 
Overview 
 Protein acetylation is an important, reversible post-translational modification that 
affects protein-DNA interactions, protein stability and protein-protein interactions1. Lysine 
acetyltransferases (KATs) catalyze the addition of an acetyl moiety to lysine residues and 
histone deacetylases (HDACs) catalyze removal of this group. The balance of activity 
from these two families of enzymes regulate the acetylation state of proteins involved in 
many cellular roles2. Aberrant acetylation, along with differential expression of various 
HDACs, has been observed in a variety of disease states3–7. Thus, it is important to 
discover not only the specificity of each HDAC isozyme, but also their downstream effects 
during the progression of diseases. 
 HDAC8, a class I isozyme, has been biochemically characterized in vitro8–10. 
However, its current cellular role is still under investigation. Identification of HDAC8 
substrates has proven difficult at least partly due to lack of improved assay methods for 
measuring HDAC activity and substrate promiscuity between other HDACs. 
Recent proteomic studies utilizing mass spectrometric approaches11,12 have 
provided evidence for multiple potential HDAC8 substrates12–14. One of the best validated 
HDAC8 substrates discovered through these studies is the structural maintenance of 
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chromosomes 3 (SMC3)6. SMC3 is a component of the cohesin complex, which is a highly 
regulated multi-protein assembly that ensures cohesion and proper separation of sister 
chromatids during the cell cycle. The complex consists of four components: SMC1A, 
SMC3, RAD21 and STAG15, which form a quaternary ring-like structure that is capable of 
encasing two sister chromatids at a time (Figure 3.1)15,16. SMC1A and SMC3 each contain 
a long, antiparallel coiled-coil that separates their hinge and ATPase domains. SMC1A 
and SMC3 associate through these hinge and ATPase domains and this complex is 
stabilized through the binding of RAD21. The last protein in the complex, STAG1/2, binds 










 Figure 3.1 – Quaternary structure of the cohesin complex  
Figure adapted from 33. The cohesin complex consists of four protein elements that encase sister 
chromatids during cell division: SMC1A, SMC3, RAD21 and STAG1/2. Post-translational 
modifications, such as acetylation, are important for the regulation and assembly of this quaternary 
complex. 
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 Mutations in the genes that encode these core proteins have given rise to Cornelia 
de Lange spectrum (CdLS) disorders. CdLS disorders, also referred to as 
cohesinopathies, encompass a wide range of phenotypes characterized by skull and limb 
abnormalities, stunted physical growth, and mental disabilities typically coupled with 
cardiovascular and nervous system problems17,18,19. The prevalence of CdLS is very low, 
at an estimate of 1 – 2 individuals per 100,000 births20.  
 It was recently discovered that additional proteins outside the cohesin complex, 
including HDAC8, play a critical role in regulating its function. Misregulation of these 
proteins can also lead to CdLS phenotypes6. Evidence suggests that cohesion of sister 
chromatids occurs in tandem with the acetylation of SMC3 at residues K105 and K106 
catalyzed by the lysine acetyltransferases ESCO1 and ESCO221. The acetylation of these 
residues blocks activity of one of the ATPase sites in the complex that normally facilitates 
ring opening22. Dissociation of the complex is initiated during the prophase and finalized 
during the anaphase15. The opening of the cohesin ring is required for the proper 
separation of sister chromatids. Current evidence suggests that HDAC8 catalyzes the 
deacetylation of K105 and K106 in SMC3, leading to dissociation of the complex.  
To date, a total of 16 missense mutations have been identified in the gene 
encoding for HDAC8 in patients with CdLS conditions6. Many of these mutations have 
resulted in partial or complete loss of in vitro deacetylase activity. Ten of these HDAC8 
mutants have been biochemically characterized with three dimensional crystal structures, 
thermostability measurements and basic biochemical assays using a methylcoumarin 
peptide23,24. 
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 In this study, we investigate the effects of three HDAC8 mutants (P91L, I243N, 
T311M) with varying deacetylase activities to further analyze the functional effects of the 
mutations including secondary structure, divalent metal ion affinity and catalytic activity 
















Figure 3.2 – Selected HDAC8 CdLS mutations  
Single HDAC8 mutations used in this study are shown on the tertiary structure of HDAC8. These 
point mutations (PDB: 2v5w) were selected due to their previously reported wide range of effects 
on HDAC8 activity previously published23,24. 
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Materials and Methods 
Materials 
 Unless specified, chemicals and supplies were purchased from Sigma. All 
chemicals were purchased at the highest quality available. Chromatography resins were 
purchased from GE Healthcare. 
HDAC8 Purification 
 Both HDAC8 WT and CdLS mutants (P91L, I243N and T311M) were prepared 
using the following method, modified from (8). HDAC8 mutants were constructed using 
PCR-based site directed mutagenesis to replace the wild-type (WT) codon at: Pro91 
(CCG) with the codon for Leu (CTG); Ile243 (ATT) with the codon for Asn (AAC); and 
Thr311 (ACC) with the codon for Met (AUG). HDAC8-TEV-His6 was transformed into 
BL21-DE3 Z-competent cells, grown on LB/ampicilin media plates and then inoculated 
into 2xYT media supplemented with 100 μg/mL of ampicillin at 37ᵒC at 170 RPM until 
OD600 = 0.4 - 0.7. The temperature was then decreased to 20ᵒC for 45 – 60 minutes, 
followed by induction with isopropyl β-D-1-thiogalactopyranoside (IPTG) (0.5 mM) and 
addition of ZnSO4 (0.2 mM). Cells were harvested 15 - 16 hours post-induction by 
centrifugation (4000 x g, 15 minutes, 4ᵒC) and the pellets were resuspended in HDAC8 
buffer A (30 mM HEPES pH 8.0, 150 mM NaCl, 1 mM imidazole, 1 mM TCEP, 5mM KCl) 
supplemented with a complete protease inhibitor cocktail tablet (Roche). Cell were lysed 
using a microfluidizer (Microfluidics) followed by centrifugation (27,000 x g, 45 minutes, 
4ᵒC). The cleared lysate was loaded onto a Ni2+-charged chelating sepharose (GE 
Healthcare) gravity column equilibrated with HDAC8 buffer A. The column was washed 
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with 20 mM imidazole in buffer A and HDAC8 was eluted in a linear gradient using buffer 
B (30 mM HEPES pH 8.0, 150 mM NaCl, 200 mM imidazole, 1 mM TCEP, 5 mM KCl). 
The His6 tag was cleaved by addition of 1 mg/mL His6-tagged TEV protease during an 
overnight dialysis using HDAC8 buffer A without imidazole at 4ᵒC. A second, stepwise-
elution Ni2+-charged column was used to separate HDAC8 from TEV protease. HDAC8 
was eluted in the flow through and 20 mM imidazole step gradients. HDAC8 was 
concentrated in 10k or 30k MWCO Amicon Ultra centrifugal concentrators and dialyzed 
to remove metal using metal-free reagents (25 mM MOPS pH 7.5, 1 mM TCEP, 5 mM 
KCl and 1 mM EDTA). This was followed by multiple dialyses (25 mM MOPS pH 7.5, 1 
mM TCEP, 5 mM KCl) to remove EDTA. HDAC8 was then aliquoted, flash frozen in liquid 
nitrogen and stored at -80ᵒC. Concentration was measured by absorbance at 280 nm 
using the extinction coefficient of 52,120 M-1cm-1, which was determined previously8. 
HDAC8 CdLS activity with a Methylcoumarin labeled peptide 
 The catalytic activities of HDAC8 WT and CdLS mutants were measured using the 
Fluor de Lys tetrapeptide assay substrate Ac-Arg-His-Lys(ac)-Lys(ac)-
aminomethylcoumarin (Enzo Life Sciences). Deacetylation of the substrate by HDAC8 is 
followed by the cleavage of the amino bond linking the C-terminal methylcoumarin to the 
peptide backbone catalyzed by trypsin, resulting in a fluorescence shift between the 
deacetylated product (ex. = 430 nm, em. = 450 nm) and the remaining substrate (ex. = 
340 nm, em. = 380 nm). Fe2+ and Zn2+ were bound to apo-HDAC8 (10 μM) by incubation 
in a ratio of 5:1 and 1:1 metal: HDAC8, respectively, on ice for 1 hour prior to dilution into 
the assay. Activity assays were performed at 25ᵒC in HDAC8 assay buffer (25 mM HEPES 
pH 7.8, 137 mM NaCl, 3 mM KCl). Zn2+-HDAC8 CdLS mutants (1 μM) were measured 
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using 50 μM substrate and Fe2+-HDAC8 CdLS mutants (1 μM) were measured using 100 
μM substrate. The data were fit using a linear equation and kcat/KM was calculated from 
these data assuming a linear dependence on substrate concentration, as previously 
demonstrated for WT-HDAC88. 
Measurement of Circular Dichroism (CD) of HDAC8 CdLS Mutants 
 The secondary structure for each HDAC8 CdLS mutant was measured using 
circular dichroism. HDAC8 CdLS mutants were reconstituted (5 μM) as apo-HDAC8 or at 
a molar ratio of 1:1 with Zn2+ in HDAC8 assay buffer (25 mM HEPES, pH 7.8, 137 mM 
NaCl, 3 mM KCl) for 1 hour on ice. CD measurements were carried out at a concentration 
of 5 μM for each mutant and performed using a JASCO J-1500 CD Spectrophotometer 
with a 0.1 cm path length cell. Spectra were acquired at 25 ᵒC using a bandwidth of 2 nm, 
a scan rate of 100 nm/min and averaging spectra over 61 continuous scans.  
Measurement of Metal (Zn2+/Fe2+) dissociation constants (KDMe) of CdLS Mutants 
 The affinities of HDAC8 CdLS mutants for Zn2+ and Fe2+ were measured using 
changes in anisotropy by coupling the binding of fluorescein-labeled suberoylanilide 
hydroxamic acid (fl-SAHA) to metal binding25. Fl-SAHA has a comparable binding affinity 
to both Zn2+-HDAC8 and Fe2+HDAC8 when compared to SAHA, thus we can monitor 
HDAC8 metal binding based on the concentrations of metal found in solution. These 
reactions were carried out in 1x assay buffer containing 50 nM fl-SAHA. Fluorescence 
anisotropy assays were performed in a half-area black 96-well microplate by monitoring 
the anisotropy signal of fluorescein (λex = 485 nm and λem = 535 nm) using a TECAN plate 
reader. For metal affinity measurements, apo-HDAC8 WT and mutants (1 – 10 μM) were 
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incubated with 1 mM nitrolotriacetic acid (NTA), 137 mM NaCl, 3 mM KCl, 10 mM MOPS 
pH 7)26, and either 0 – 0.5 mM Zntotal (0 – 3.3 nM Znfree) or 0 – 950 μM Fetotal (0 – 2.6 μM 
Fe2+free) as calculated by MINEQL. The assay mixtures were incubated for 1 hour on ice 
in the anaerobic glove box for Fe2+ measurements and incubated for 10 – 30 minutes at 
RT for Zn2+ measurements, followed by addition of fl-SAHA and a 10-minute equilibration 
at 25 ᵒC before measuring anisotropy signal. Zn2+ and Fe2+ KD values were obtained by 
fitting a binding isotherm to the dependence of anisotropy on the concentration of free 
metal. Equation 3.1. which describes the change in anisotropy based on the concentration 
of metal bound, was fit to the curves.  






              (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3.1)  
HDAC8 CdLS activity with a non-methylcoumarin SMC3 K106 based peptide. 
 SMC3 10-mer (Ac-RVIGAKKacDQY-NH2) peptide (Synthetic Biomolecules) was 
purchased at > 95% purity and with an acetylated lysine corresponding to K106. CdLS 
mutants were reconstituted with either Zn2+ or Fe2+ as described previously8 with small 
modifications. Apo-HDAC8 (10 μM) was reconstituted with stoichiometric Zn2+ (Fluka) in 
peptide assay buffer (20-25 mM HEPES pH 8, 137 mM NaCl, 3 mM KCl) and incubated 
for 1 hour on ice. For Fe2+-HDAC8, apo-HDAC8 was equilibrated on ice in an anaerobic 
glove box (Coy Laboratory Products) for one hour prior to reconstitution. Solid FeCl2 
(Sigma), L(+)-ascorbic acid (Fluka), and peptide assay buffer were equilibrated in the 
anaerobic chamber at least overnight before using. Fe2+ (100 μM) in 5 mM ascorbate and 
assay buffer was prepared daily. Fe2+-HDAC8 (10 μM) was reconstituted anaerobically 
by incubating with 5-fold excess Fe2+ in assay buffer and 2.5 mM ascorbate for 1 hour in 
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a 0 – 4ᵒC CoolBox (Biocision). Fe2+-HDAC8 assays were performed anaerobically. The 
enzyme-coupled assay was performed as described27. Fe2+ and Zn2+-HDAC8 CdLS 
mutants and peptides in assay buffer were independently equilibrated at 30 ᵒC for 15 
minutes prior to reaction initiation. Reactions were initiated by the addition of enzyme (WT 
and P91L = 1 μM, I243N = 5 μM and T311M = 2 μM) to various concentrations of SMC3 
K106 peptide (0 – 300 μM). Time points were quenched with 10% hydrochloric acid (HCl), 
flash frozen in liquid nitrogen, and stored at -80ᵒC. Assay workup was performed as 
described27. Assay standards were prepared using acetic acid (Ricca Chemical 
Company). After thawing, time points were neutralized with 6% sodium bicarbonate 
(NaHCO3), and centrifuged (16,000 x g, 1 minute), and added to equilibrated coupled 
enzyme solution in a 96-well plate (Corning #3686) and incubated for 30 minutes prior to 
reading. The fluorescence of the resulting NADH was measured (ex. = 340 nm, em. = 
460 nm). Either the Michaelis-Menten equation (MM) or a line was used to calculate 
kinetic parameters (kcat, KM and kcat/KM). Initial rates were calculated from the 
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Results 
HDAC8 CdLS catalysis using a methylcoumarin peptide 
 To define the catalytic function of these residues (P91L, I243N and T311M) in 
HDAC8 that are mutated in CdLS patients, we measured the catalytic activity of HDAC8 
WT and CdLS mutants with either bound Fe2+ or Zn2+ using the Fluor de Lys (FdL) assay. 
The kinetic parameter (kcat/KM, app) was determined from a linear fit of the dependence of 
the initial rate of product formation on the concentration of substrate. 
 HDAC8 P91L was the most active of the measured mutants (>70-80% of WT 
activity) with both bound Fe2+ and Zn2+ (Table 3.1), consistent with previously published 
data24 for the Zn2+ enzyme. The I243N mutation has a larger effect on catalytic turnover, 
with only 10% residual activity remaining with either Fe2+ or Zn2+ when compared to WT 
(Table 3.1). Surprisingly, this was the only HDAC8 mutant not consistent to previous data 
for the Zn2+ enzyme23, which demonstrated 40% residual activity. Interestingly, the T311M 
mutation has the largest effect on catalysis, with overall residual activity of less than 5% 
for either bound divalent metals when compared to WT (Table 3.1).  
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CD measurements of HDAC8 CdLS mutants 
 Circular dichroism measures the overall secondary structure of proteins. Our 
measurements showed that the mutants’ spectra are nearly identical to that of WT-
HDAC8, suggesting retention of secondary structure, despite the loss of activity (Figure 
3.3). All spectra were evaluated using BeStSel (Beta Structure Selection) secondary 
structure prediction program for CD28. All of the CdLS mutant spectra retained similar 
secondary structure calculations as WT-HDAC8, with ~15% α-helicity, ~30-35% β-sheet 
and ~35% random coil character. These data indicate that none of the mutations cause 
large disruptions in the overall protein structure. Thus, it is possible that the catalytic 
activity of HDAC8 CdLS mutants is altered by small rearrangements rather than major 
structural changes. It is possible that these HDAC8 mutant proteins could still bind to 
substrates and interacting proteins but do not catalyze deacetylation. 









Figure 3.3 – CD spectra of HDAC8 WT and CdLS mutants 
CD spectra of WT (A), P91L (B), I243N (C), and T311M (D) as apo enzyme (black) and Zn2+-
bound enzyme (red). The spectra reflecting the overall structure remains unmodified between 
all mutants. These spectra were used to predict secondary structure using the BeStSel 
prediction program. 
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Measurements of divalent metal binding affinity of CdLS mutants 
 Given that these mutations do not affect the overall structure but instead alter the 
activity of both Zn2+ and Fe2+-HDAC8, we tested the importance of each of these mutants 
in determining metal selectivity by measuring the dissociation constant (KD) for both Zn2+ 
and Fe2+ in HDAC8. For these experiments, apo-HDAC8 was equilibrated with various 
concentrations of free metal ions in NTA-buffered solutions. The amount of metal bound 
HDAC8 was determined by the binding of fl-SAHA, which preferentially binds to 
metallated HDAC825. Fluorescence anisotropy displays a hyperbolic dependence on free 
metal concentration (Figure 3.4). To verify the accuracy of this method, we measured the 
affinity of WT HDAC8 for metal and obtained similar results to previously reported data25. 
 Metal affinity was measured for each CdLS mutant with both Zn2+ and Fe2+-NTA 
buffered solutions. P91L displayed identical divalent metal binding affinities as compared 
to WT HDAC8 (Table 3.2 and Figure 3.5). This led us to the hypothesis that the effect of 
this mutation on catalysis is mostly due to perturbation of binding loops, which can affect 
both substrate binding and product release. The two other mutants, I243N and T311M, 
displayed altered affinities. Both mutants have similar (within 2-fold) binding affinities for 
Fe2+ when compared to WT HDAC8, however, Zn2+ affinity was decreased by at least 
























Figure 3.4 – HDAC8 metal binding affinity scheme using fl-SAHA 
General scheme for HDAC8 divalent metal binding. Fluorescein-SAHA (fl-SAHA) binds with high 
affinity to metal bound HDAC8, allowing for coupling of metal binding to fl-SAHA as indicated by 
changing fluorescence anisotropy. Apo-HDAC8 does not binding fl-SAHA while any metal-
reconstituted HDAC8 species will display a change in anisotropy. 














Figure 3.5 – Metal binding affinities of HDAC8 CdLS mutants 
Measurement of metal binding affinities for (A) Zn2+-bound and (B) Fe2+-bound WT-HDAC8 (■), 
P91L (▲), I243N (▼) and T311M (♦). Measurements were done using NTA-buffered metal solutions 
in the presence of fl-SAHA. A binding isotherm is fit to the data (Equation 3.1) 
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HDAC8 CdLS activity using an SMC3 mimic peptide 
 To date, all in vitro activity assays with CdLS mutants have been done using the 
FdL peptide6,23,24. We sought to test each HDAC8 CdLS mutant with a biologically 
relevant peptide, SMC3 10-mer, to obtain insight into possible effects of SMC3 
deacetylation. To measure deacetylation, we used an enzyme-coupled assay that 
measures the stoichiometric exchange of acetate product to NADH using fluorescence27. 
Assays were performed with both Zn2+ and Fe2+- HDAC8 CdLS mutants under multiple 
turnover conditions and the dependence of the initial rates of deacetylation were used to 
calculate catalytic efficiencies. The dependence of the initial rate on the peptide 
concentration for WT and all CdLS mutants are shown in Figure 3.6. The catalytic 
efficiencies (kcat/KM) for CdLS mutants ranged from < 5 M-1s-1 for the Zn2+ enzyme and < 
5 – 100 M-1s-1 for the Fe2+ enzyme (Table 3.3).  





Figure 3.6 – Catalytic efficiencies of HDAC8 CdLS mutants on an SMC3 
mimic peptide. 
Deacetylation of an SMC3 10-mer peptide (50 – 200 μM) catalyzed by (A) Zn2+ and (B) Fe2+ bound 
WT HDAC8 (■), P91L (▲), I243N (▼) and T311M (♦). Reactions were initiated by the addition of 
enzyme (1 – 5 μM) to peptide in 20-25 mM HEPES pH 8, 137 mM NaCl, 3 mM KCl at 30ᵒC. 
Reactions were quenched at various times and the acetate concentration produced was determined 
using an enzyme coupled assay. Data was collected for up to 4 hours per reaction and the initial 
rates were calculated from a linear fit to the time dependence. The Michaelis-Menten equation or a 
line were used to fit the concentration dependence of the initial rates to calculate kinetic parameters. 
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 Our data demonstrates an overall decrease in SMC3 deacetylase activity for all 
CdLS mutants when compared to WT-HDAC8. It is worth noting that SMC3 deacetylation 
and FdL peptide percent deacetylation is comparable for most mutants, except for P91L, 
which displays a slower deacetylation of the SMC3 peptide in comparison to FdL peptide 
deacetylation.  
Discussion 
HDAC8 has recently been associated with Cornelia de Lange Spectrum Disorders 
(CdLS) through the use of RNA interference-based screening and monitoring loss of 
HDAC8 activity using an HDAC8-specific inhibitor6, making it one of the first validated 
HDAC8 substrates. Nearly all the mutations identified in HDAC8 associated to CdLS are 
in randomly distributed regions and not near the active site as predicted. Interestingly, 
some of these mutations affect HDAC8 catalysis in a variety of ways. This study provides 
insight into the chemistry and the variety of effects that some of these mutations have on 
HDAC8 catalysis, which in turn can be used to understand how the overall structure of 
HDAC8 plays a role in deacetylation. 
P91 residue is located in the L2 loop, which flanks one section of the active site 
surface and has been proposed to aid in the binding of both substrates and inhibitors by 
its positioning in crystallographic studies10,29,30. It has been hypothesized that the L2 loop 
is essential in peptide-substrate binding due to this intrinsic flexibility29,30. In our study, we 
observe that the P91L HDAC8 mutation behaves most similarly to WT-HDAC8, however, 
it displays the largest change in deacetylation between the FdL peptide and the SMC3 
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peptide. We hypothesize that P91L effect on activity is mainly due to decreased peptide-
substrate affinity and/or peptide-product release. 
The I243 residue is located in helix F, approximately 20 Å from the divalent metal 
ion binding site31. Mutation of isoleucine to asparagine introduces a polar residue into an 
otherwise nonpolar helix, which may destabilize the structure near a monovalent metal 
binding site. Previous studies have demonstrated that HDAC8 activity is modulated by 
monovalent metal ion binding10. Binding of potassium (K+) to the monovalent site 
activates catalytic activity in a time-dependent manner10. We hypothesize that mutations 
near this site could either significantly decrease K+ binding to the site and inhibit activation 
or allow K+ binding without activation. The unexpected effect of this mutation is that it does 
not affect the affinity of Fe2+. Our data provides evidence that deacetylation of both FdL 
and SMC3 peptides is slow with either Zn2+-bound and Fe2+-bound HDAC8, and Fe2+ 
binding affinity remains similar to WT-HDAC8 while Zn2+ is decreased by at least 103-fold. 
We hypothesize that there could be a difference between HDAC8 metalloforms that this 
mutation could potentially alter, we discuss this difference and a potential transient 
mechanism in-depth in chapter five. 
The T311M mutation is located in the H2 helix, approximately 10 Å from the 
divalent metal ion active site. Decroos and collaborators have demonstrated that this 
mutation causes a shift in the conformation of Arg37, a “gatekeeper” residue of the 
acetate release channel23. This shift breaks the hydrogen bonds with the backbones of 
Gly303 and Gly305 compromising product release. Additionally, crystallographic data 
shows that the shift of Arg37 causes the L1 loop (Leu31-Pro35) to reorganize. This loop 
has been shown to influence substrate binding through a substrate-enzyme hydrogen 
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bond with Lys3329,30. Our data shows that this mutant is the most detrimental towards 
catalysis using both the FdL and SMC3 peptides with either Zn2+ or Fe2+-bound HDAC8. 
We hypothesize that the T311M mutation affects both the L1 and L2 loop indirectly by 
disrupting hydrogen bond interactions within HDAC8, affecting both peptide-substrate 
binding and product release. 
Conclusions 
 Overall, our work provides insight into the kinetic and catalytic effects of CdLS point 
mutations on HDAC8. We demonstrated that the P91L mutation affects overall substrate 
release through disruptions of the L2 loop region, which is important for both substrate 
binding and product release. The I243N and T311M mutations affect the divalent metal 
ion binding site by affecting the internal bonding network of HDAC8 while still retaining its 
overall secondary structure, as supported by simulation studies23,24. We also provide the 
first evidence of SMC3 peptide deacetylation by the P91L and I243N mutants. 
Additionally, with their retained structure, these mutants could be further functionalize 
using crosslinking probes and click chemistry to identify HDAC8-substrate interactions in 
vivo. Further characterization of the other 13 CdLS mutants will be needed to highlight 
the role of each mutant on SMC3 deacetylation and their extended downstream effects 
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Chapter 4 
Metal Switching Specificity: A Novel Regulatory Mechanism for HDAC8**,†† 
Overview 
Protein lysine acetylation is an enzymatically reversible post-translational 
modification (PTM). Acetylation is catalyzed by twenty lysine acetyl transferases (KATs) 
and eighteen lysine deacetylases, including both metal-dependent histone deacetylases 
(HDACs) and the NAD+ dependent sirtuins (SIRTs). HDACs and SIRTs catalyze 
deacetylation through hydrolysis of the acetyl moiety1. The balance of the enzymatic 
activities of both lysine deacetylases (HDACs and SIRTs) and KATs regulate the 
acetylation states of both histone proteins and non-histone proteins involved in many 
different cellular processes2. These enzyme families control the acetylation state of >6000 
acetylated sites in the mammalian proteome3, and it is therefore important to understand 
the mechanism by which each isozyme is specifically regulated4,5. HDACs are medically 
relevant enzymes because aberrant acetylation has been implicated in several disease 
states. Elucidating the determinants of substrate specificity and regulation of each HDAC 
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isozyme is important for understanding the regulatory mechanisms of 
acetylation/deacetylation in the cell and for designing isozyme selectivity in therapeutics. 
 HDAC8 is a class I isozyme and a metal dependent HDAC. HDAC8 is well 
understood biochemically, but its cellular role and regulation require further investigation. 
It is primarily expressed in human smooth muscle cells and is the only class I isozyme 
that can be found in both the nucleus and the cytoplasm6,7. The precise HDAC8 substrate 
set remain largely undefined, but predicted HDAC8 substrates include the nuclear 
structural maintenance of chromosomes 3 (SMC3)8, core histone proteins9, cAMP 
response binding protein (CREB)10, the cysteine-rich protein 2-binding protein 
(CSRP2BP)11, and the estrogen-related receptor alpha (ERRα)12,13 among others. 
HDAC8 was originally proposed to be a zinc-dependent metalloenzyme since zinc co-
purified with the enzyme and was observed in the first HDAC8 crystal structure14. 
However, several divalent metal ions can activate the enzyme. The kcat/KM trend of 
catalysis for metal-substituted HDAC8 is Co2+ > Fe2+ > Zn2+ > Ni2+ > Mn2+15.  In contrast 
to Zn2+, the activity of Fe2+-HDAC8 decreases when exposed to oxygen15. Furthermore, 
the trend of the inhibition constant, Ki, of the FDA-approved pan-HDAC inhibitor 
suberoylanilide hydroxamic acid (SAHA) is Co2+ < Fe2+ < Zn2+16, inversely proportional to 
that of kcat/KM. The fact that the enzyme can be activated by different divalent metal ions 
leads to the suggestion that HDAC8 activity in vivo may be regulated by the identity of the 
active site metal ion.  
 Crystal structures of HDAC8 have not been able to explain the metal-dependent 
differences in activation and inhibition. Structures of Fe2+- Co2+- and Zn2+-HDAC8 bound 
to hydroxamic acid inhibitors show a common pentacoordinate, square pyramidal 
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geometry for all metal-substituted forms16. However, these structures are only a snapshot 
and cannot show dynamic conformational changes and interactions that might occur 
when a peptide substrate is bound to the enzyme. Additionally, the hydroxamic acid 
inhibitor could potentially stabilize the active site metal coordination state in the fixed 
conformation observed in the various crystal structures, regardless of the identity of the 
bound divalent metal ion.   
 Based on these observations, the affinity of HDAC8 for each divalent metal and 
the readily available metal concentrations, HDAC8 could be activated by either Zn2+ or 
Fe2+ in vivo. Under normal conditions, readily exchangeable Zn2+ concentrations is lower 
than Fe2+ in cells; exchangeable Zn2+ concentration ranges from 5 pM – 2 nM while 
predictions of the Fe2+ concentration ranges from 200 nM – 12 μM17–19. However, the 
concentrations of zinc in cells can increase significantly, such as under conditions of 
oxidative stress17 or after telophase arrest20.  HDAC8 has a 106-fold higher affinity for 
Zn2+ compared to Fe2+, at 5 ± 1 pM and 0.2 ± 0.1 μM, respectively15,16,21. Additionally, 
HDAC8 is not activated by Fe3+. HDAC8 expressed in bacteria binds and is activated by 
Fe2+15. Furthermore, HDAC activity in mammalian cell lysates is oxygen sensitive, 
consistent with Fe2+ dependent activity15,16. Immunopurified HDAC8 in HeLa cells 
demonstrates oxygen-sensitive activity22. Together, these data suggest that iron may play 
a role in cellular HDAC8 activation and demonstrates the importance of determining which 
metals activate and regulate HDAC8 activity in vivo. 
 Prompted by the difference in divalent metal-dependent deacetylase activity and 
the observed HDAC8 oxygen sensitivity in cell lysates, we investigated whether the 
identity of the catalytic divalent metal ion affects the substrate selectivity of HDAC8-
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catalyzed deacetylation in vitro. Here we show that the divalent metal ion (Zn2+ or Fe2+) 
in the active site alters both the activity and the peptide substrate selectivity of HDAC8. 
Based on these data, we hypothesize that in vivo metal switching could regulate both the 
activity and selectivity of HDAC8. For metal switching, we propose that HDAC8 is bound 
to Fe2+ in cells, however, when the Zn2+ concentration increases the active site metal ion 
is replaced to form Zn2+-HDAC8. This work suggests a new mechanism by which peptide 
specificity and deacetylase activity of HDAC8 may be regulated in vivo. 
 
Materials and Methods 
 Metal free HEPES, NaCl, KCl, and NaOH were purchased from Sigma, and  TCEP 
(tris(2-carboxylethyl)phosphine) was purchased from GoldBio. All other reagents were 
purchased from Fisher unless otherwise specified. 
HDAC8 Purification 
 HDAC8 was prepared using the following method, modified from (15). HDAC8-
TEV-His6 was transformed into BL21-DE3 Z-competent cells and grown in 2xYT media 
supplemented with 100 μg/mL of ampicillin at 37ᵒC with shaking at 170 RPM until OD600 
= 0.4 - 0.7. The temperature was then decreased to 20ᵒC for 45 – 60 minutes, followed 
by induction with isopropyl β-D-1-thiogalactopyranoside (IPTG) (0.5 mM) and addition of 
ZnSO4 (0.2 mM). Cells were harvested 15-16 hours post-induction by centrifugation (4000 
x g, 15 – 20 minutes, 4ᵒC) and resuspended in HDAC8 resuspension buffer (30 mM 
HEPES pH 7.8-8.0, 150 mM NaCl, 5 mM KCl, 1 mM imidazole, and 1 mM TCEP) 
supplemented with a complete protease inhibitor cocktail tablet (Roche). Cells were lysed 
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by microfluidizer (Microfluidics), followed by nucleic acid precipitation with 
polyethyleneimine (pH 7.9) and followed by centrifugation (27,000 x g, 45 minutes, 4ᵒC). 
HDAC8 was loaded onto a Ni2+-charged chelating sepharose (GE Healthcare) gravity 
column equilibrated with HDAC8 purification buffer (30 mM HEPES pH 8, 150 mM NaCl, 
5 mM KCl, 1 mM TCEP and 1 mM imidazole). The column was washed with 20 mM 
imidazole purification buffer and HDAC8 was eluted using a linear gradient (25 – 250 mM 
imidazole). The His6 tag was cleaved using His6-tagged TEV protease during an 
overnight dialysis against HDAC8 purification buffer without imidazole. A second, 
stepwise-elution Ni2+-charged column was used to separate HDAC8 from TEV protease. 
HDAC8 eluted in the flowthrough and 20 mM imidazole steps. HDAC8 was concentrated 
in 10k or 30k MWCO Amicon Ultra centrifugal concentrators and dialyzed against metal 
free buffer A (25 mM MOPS pH 7.5, 1 mM TCEP, 5 mM KCl and 1 mM EDTA) followed 
by several dialyses against metal free buffer B (25 mM MOPS pH 7.5, 1 mM TCEP, 5 mM 
KCl). For MALDI deacetylation assays, a PD-10 desalting column (GE Healthcare) in 
either PD-10 buffer A (25 mM HEPES pH 7.4 – 7.8, 150 mM NaCl, 3 mM KCl, 1 mM 
TCEP) or PD-10 buffer B (25 mM MOPS pH 7.5, 1 mM TCEP) was used to remove 
residual EDTA. HDAC8 was aliquoted, flash frozen in liquid nitrogen, and stored at -80ᵒC. 
Concentration was measured by absorbance at 280 nm using the extinction coefficient of 
52,120 M-1cm-1, which was determined previously15. ICP-MS confirmed less than 10% 
Zn2+ present in the final enzyme sample. 
High-throughput SAMDI mass spectrometry deacetylation assays 
 Selectivity screens were performed using Self-Assembled Monolayers for MALDI-
TOF Mass Spectrometry (SAMDI). The SAMDI assays were performed as previously 
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published23–26. Peptides of varying sequence were transferred to an array plate containing 
384 gold islands, each with a monolayer presenting a maleimide group at a density of 
10% against a background of tri(ethylene glycol) groups. In this way, the peptides were 
immobilized through reaction of the side chain of the terminal cysteine residue with 
maleimide while the glycol groups prevent non-specific adsorption of proteins onto the 
monolayer. The peptide array was incubated with HDAC8 by distributing 3 μL portions of 
a solution (0.5 μM enzyme, 25 mM Tris pH 8.0, 147 mM KCl, 3mM NaCl) using a 12-
channel pipette. Solutions were kept at 37ᵒC for 30 minutes followed by stopping the 
reaction by rinsing the array plate with ethanol. Separate controls were performed using 
ICP-MS to measure metal bound to HDAC8 after incubation with the SAMDI plates. 
Separate controls were performed using ICP-MS to measure metal contamination in 
HDAC8 reactions from several SAMDI plates. Zn2+ contamination ranged between 0.3 – 
0.6 μM in the control assays tested.  
Enzyme-coupled assay for in solution non-methylcoumarin peptides 
 Peptides (Peptide 2.0 and/or Synthetic Biomolecules) were synthesized with 
acetylated N-termini and carboxamide C-termini. Zn2+-HDAC8 and Fe2+-HDAC8 were 
reconstituted as described15. Apo-HDAC8 (10 μM) was reconstituted with stoichiometric 
Zn2+ (Fluka) in peptide assay buffer (25 mM HEPES pH 8, 137 mM NaCl, 3 mM KCl) and 
incubated for 1 hour on ice. For Fe2+-HDAC8, apo-HDAC8 was equilibrated in an 
anaerobic glove box (Coy Laboratory Products) for one hour prior to reconstitution. Solid 
FeCl2 (Sigma), L(+)-ascorbic acid (Fluka), and peptide assay buffer were equilibrated in 
the anaerobic chamber at least overnight. Fe2+ (100 μM) in 5 mM ascorbate and assay 
buffer was prepared daily. Fe2+-HDAC8 (10 μM) was reconstituted anaerobically with 5-
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fold excess Fe2+ in assay buffer and 2.5 mM ascorbate for 1 hour in a 0 – 4ᵒC CoolBox 
(Biocision). Assays were performed aerobically on ice within 2 hours, the effective 
working time for ascorbic acid to preserve Fe2+ activity27. The enzyme-coupled assay was 
performed as described28. Fe2+- and Zn2+-HDAC8 and peptides in assay buffer were 
equilibrated at 30ᵒC for 15 minutes prior to reaction initiation. Reactions were initiated by 
the addition of enzyme (1 μM) to various concentrations of substrates (25 – 400 μM). 
Time points were quenched with 10% hydrochloric acid (HCl), flash frozen in liquid 
nitrogen, and stored at -80ᵒC. Assay workup was performed as described28. Standards 
were prepared using acetic acid (Ricca Chemical Company). After thawing, time points 
were neutralized with 6% sodium bicarbonate (NaHCO3), centrifuged (16,000 x g, 1 
minute), and added to an equilibrated coupled enzyme solution in a 96-well plate (Corning 
#3686). The fluorescence of the resulting NADH was measured (ex. = 340 nm, em. = 460 
nm) and the initial rate was calculated from the time dependence of NADH appearance. 
Michaelis-Menten parameters (MM) or a line was fit to the concentration dependence of 
the initial rate to calculate kinetic parameters (kcat, KM and kcat/KM). 
Assay for measuring methylcoumarin-labeled peptides 
 Peptides containing a methylcoumarin-bound C-terminus were measured using 
the Fluor de Lys (FdL) assay (Enzo Life Sciences) conditions. Deacetylation of the 
substrates by HDAC8 is followed by cleavage of the amino bond linking the C-terminal 
methylcoumarin to the peptide backbone catalyzed by trypsin, resulting in a fluorescence 
shift between the deacetylated product (ex. = 340 nm, em. = 450 nm) and the remaining 
substrate (ex. = 340 nm, em. = 380 nm). Fe2+- and Zn2+-HDAC8 were reconstituted and 
equilibrated as described previously. Reactions were initiated by the addition of enzyme 
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(1 μM) to various concentrations of substrates (25 – 200 μM). Time points were quenched 
by the addition of trichostatin A (TSA) and trypsin developer. The initial rate was 
calculated from the time dependence of the changes in fluorescence. Michaelis-Menten 
parameters (MM) or a line was fit to the concentration dependence of the initial rate to 
calculate kinetic parameters (kcat, KM and kcat/KM). 
Results and Discussion 
Mass spectrometry screen 
 To identify potential differences in selectivity with different active site metals bound 
to HDAC8, we screened HDAC8 reactivity with a 361-peptide array using self-assembled 
monolayers for matrix assisted laser desorption/ionization time-of-flight mass 
spectrometry (SAMDI) assays24. The peptides were of the form GXKAcZGC, where the 
flanking residues X and Z were varied across nineteen amino acids (all natural residues 
excluding cysteine). After incubation with HDAC8, the monolayers were analyzed by 
matrix-assisted laser desorption-ionization mass spectrometry to observe the substrate 
and product of the reaction from their masses (Figure 4.1). The fraction deacetylation of 
each peptide was determined by the ratio of the deacetylated peak area to the sum of the 
peak areas for the substrate and product. 
 We prepared HDAC8 reconstituted with Fe2+ or Zn2+ and incubated each of these 
enzyme forms with the peptide array. In both cases, we observed deacetylation of multiple 
substrates. For Zn2+-HDAC8, 172 of the peptides showed no significant reactivity (<3% 
deacetylation), 72 peptides showed moderate reactivity (3 – 15% deacetylation) and 117 
peptides showed high reactivity (>15% deacetylation). Similarly, for Fe2+-HDAC8, 139 of 
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the peptides showed no significant activity, 62 peptides showed moderate activity and 
160 peptides showed high activity. Overall, the number of active peptides was higher for 
Fe2+-HDAC8 (222 peptides) than for Zn2+-HDAC8 (189 peptides). Deacetylation heat 
maps were generated for both Zn2+- (Figure 4.1A) and Fe2+-HDAC8 (Figure 4.1B).  These 
assays suggested general peptide sequence specificity trends for HDAC8. One particular 
trend showed that all but three peptides containing an aromatic residue (Phe) at the Z 
position were deacetylated efficiently by both Zn2+- and Fe2+-HDAC8, while a methionine 
in the Z position was largely unfavorable to both enzyme forms and was observed in many 
of the non-substrate peptides. Therefore, these data demonstrated that HDAC8 substrate 
selectivity depends on the immediate sequence surrounding the acetyl lysine, consistent 
with previous results25,29. 
 To examine differences in relative activity between the two metal forms of the 
enzyme, we generated a selectivity map that displays the ratio of Zn2+-HDAC8 to Fe2+-
HDAC8 product conversion (Figure 4.1C). This heat map demonstrates that the substrate 
selectivity of HDAC8 depends on the identity of the bound divalent metal ion. In the 
screen, Zn2+-HDAC8 had higher reactivity (relative product conversion was greater than 
7-fold) than Fe2+-HDAC8 for approximately 10% of the peptides and Fe2+-HDAC8 
deacetylated 13% of the peptides to a greater extent (by a factor of at least 7-fold) than 
Zn2+-HDAC8. Many peptides displayed similar reactivity; 31% of peptides were 
comparably deacetylated by both enzyme forms and 46% of peptides demonstrated 
negligible deacetylation by both enzyme forms. Overall, these data showed that HDAC8 
substrate selectivity is altered by the identity of the active site metal ion as well as the 




Figure 4.1: HDAC8 metal specificity peptide screen 
The selectivity of (A) Zn2+- and (B) Fe2+-bound HDAC8 was evaluated by incubating each enzyme 
form with an array of 361 immobilized peptides of sequence GXKACZGC. The extent of deacetylation 
of each peptide is shown in grey scale. (C) A heat map indicating alterations in peptide selectivity 
dependent on the metal ion bound to HDAC8 was generated by taking the ratio of Zn2+-HDAC8 to 
Fe2+-HDAC8 product conversion. Peptides with a ratio that is greater than seven-fold (Zn2+-HDAC8 
selective) are shown in blue and peptides with a ratio < 0.14 Fe2+-HDAC8 (Fe2+-HDAC8 selective) 
are shown in red. Peptides that were deacetylated by both metalloenzyme forms are shown in grey 
and non-substrate peptides for both enzyme forms are shown in white. 
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Kinetic assays with in vitro protein-based peptide substrates 
 To further investigate the differences in peptide selectivity due to the identity of the 
divalent metal bound, we measured kinetic parameters for reactivity with peptide 
substrates. We selected peptides (Table 4.1) based on biologically relevant putative in 
vivo substrates as predicted by proteomic and computational methods11,30, and measured 
HDAC8-catalyzed deacetylation under steady-state conditions. We compared kcat/KM 
(catalytic efficiency) values for Fe2+- and Zn2+-HDAC8. 
 To determine HDAC8 reactivity, we used an enzyme-coupled deacetylation assay 
that measures the stoichiometry of acetate formation to NADH using changes in 
fluorescence. Additionally, we measured deacetylation of methylcoumarin-bound 
peptides as a benchmark for Fe2+/Zn2+ selectivity, as previously described15. Both 
stopped assays were performed using Zn2+ or Fe2+-HDAC8 under multiple turnover 
conditions to measure the initial rates of peptide deacetylation.  The kcat/KM values were 
calculated from the dependence of the initial rates on the substrate concentration, as 
shown for both non-coumarin (Figure 4.2) and coumarin-bound (Figure 4.3) peptides. The 
catalytic efficiencies for the peptides ranged from 2 – 500 M-1s-1 for Zn2+-HDAC8 and 3 – 
6000 M-1s-1 for Fe2+-HDAC8. The specificity constant for Fe2+-HDAC8 was higher for most 
peptides tested, however, the ratio of the kcat/KM values for the two metalloenzyme forms 
varied significantly, as predicted from the original immobilized peptide screen. The ratios 































Figure 4.2: Representative data of metal-dependent reactivity of HDAC8 with 
a non-methylcoumarin labeled peptide  
Dependence of the initial rates for Zn2+-HDAC8- (●) and Fe2+-HDAC8- (■) catalyzed deacetylation 
on the concentration of a SMC3-derived 10-mer peptide (50 – 300 μM). Reactions were initiated by 
addition of enzyme (1 μM) in 25 mM HEPES pH 8, 137 mM NaCl, 3 mM KCl at 30ᵒC.  After quenching 
the reaction, acetate product was coupled to the formation of NADH, as measured by fluorescence. 








Figure 4.3: Representative data of metal-dependent reactivity of HDAC8 with 
a methylcoumarin labeled peptide  
Dependence of the initial rates for Zn2+-HDAC8- (●) and Fe2+-HDAC8- (■) catalyzed deacetylation 
on the concentration of a SIRT1 C-terminal methylcoumarin peptide (20 – 150 μM). Reactions were 
initiated by addition of enzyme (1 μM) in 25 mM HEPES pH 8, 137 mM NaCl, 3 mM KCl at 30ᵒC.  
After quenching the reaction, free methylcoumarin was monitored through fluorescence using the 









Figure 4.4: Ratio of kcat/KM values catalyzed by Fe2+/Zn2+ HDAC8 for various 
peptide substrates 
The values of kcat/KM were calculated from the dependence of the initial rates on the peptide 
concentration (25 – 400 μM) catalyzed by 1 μM HDAC8 in assay buffer.  The ratios of the kcat/KM 
values for Fe2+-HDAC8 / Zn2+-HDAC8 are shown.  The error was calculated using the equation 
listed in the legend of Table 4.1. 
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For the peptides measured, the kcat/KM values Fe2+-HDAC8 are higher than values 
for Zn2+-HDAC8 for all except one peptide (THRAP3). The ratios of the kcat/KM values 
catalyzed by Fe2+-/Zn2+ HDAC8 vary from 0.3 to 17 (Table 4.1) further demonstrating that 
substrate selectivity is dependent on the identity of the active site metal ion.  For the non-
coumarin peptides, the increased selectivity ratio generally correlates with an increase in 
the value of kcat/KM for reaction of a peptide with Fe2+-HDAC8 with the exception of the 
LARP1 peptide.  In fact, there is a linear correlation between Fe/Zn selectivity ratio and 
Fe2+-HDAC catalyzed kcat/KM values (removing the LARP1 peptide data) with R = 0.8.  
This suggests that the differential reactivity for the majority of peptides is mainly explained 
by an increased reactivity with Fe2+-HDAC8 relative to Zn2+-HDAC8.  Therefore, these 
data suggest alterations in the structure or dynamics of the Fe2+-substituted HDAC8 that 
lead to enhanced interactions with peptides that increase binding affinity and/or reactivity 
of the catalytic metal-bound water nucleophile.  From crystal structures, we know that the 
HDAC8 divalent metal ion active site is in a square planar coordination15,16,31. However, 
these crystal structures have hydroxamic acid inhibitors bound and we think it is possible 
that these inhibitors restrict the conformations that the active site metal ion can adapt. We 
propose that Fe2+-HDAC8 can adopt other coordination motifs in the absence of bound 
inhibitors, such as a trigonal bipyramidal conformation, and this flexibility can 
accommodate and catalyze deacetylation of more diverse substrates than Zn2+-HDAC8.  
The reactivity data (Table 4.1) suggest several potential determinants of the metal-
dependent HDAC8 substrate selectivity. The first potential determinant is peptide length. 
For the peptides based on Histone H3, an increase in peptide length from 7 to 13 amino 
acids resulted in an increase in the Fe2+/Zn2+ ratio, due to an increase in the kcat/KM value 
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for Fe2+-HDAC8 only.  This result suggests that additional HDAC8-substrate interactions 
can occur with the Fe2+-enzyme that affect substrate binding affinity or deacetylation 
activity. We hypothesize that interactions outside of short peptide sequences (i.e. long 
range interactions) are important for enhancing HDAC8 substrate specificity25. However, 
peptide length alone is not likely an important determinant of metal-dependent selectivity 
as there is no correlation between the selectivity ratio and peptide length (R = 0.06).   
The Flex-Pep-Bind analysis of peptide selectivity of HDAC8 suggests that the three 
upstream and two downstream side chains flanking the acetyllysine as well as the 
conformation of the peptide substrate are important for peptide recognition by Zn2+-
HDAC829. Based on this model, the main determinant of the metal dependent selectivity 
ratio is likely due to varied interactions with specific peptide side chains. The SMC3 
peptides provide a clear illustration of this effect since they vary only by the presence or 
absence of a tyrosine residue at the +3 position. In this case, addition of the +3 Tyr residue 
increased the activity of Zn2+-HDAC8 by 2-fold, while the Fe2+-HDAC8 activity remained 
constant, thereby decreasing the Fe2+/Zn2+ ratio from 16 (9-mer) to 6 (10-mer). It is 
possible that Zn2+-HDAC8 forms stable interactions with +3 aromatic residues that are 
not needed for Fe2+-HDAC8. 
 Furthermore, the residues flanking the acetyllysine moiety could be particularly 
important for metal-dependent HDAC8-substrate recognition. Both peptides with +1 Phe 
residues (LARP1 and CSRP2BP) are Fe2+-specific substrates with Fe2+/Zn2+ ratios 8 and 
16, respectively. These data suggest that a Phe at the +1 position enhances reactivity 
with Fe2+-HDAC8.  However this is not the only determinant of the metal-dependent 
selectivity as the SMC3 9-mer has a Fe2+/Zn2+ ratio of 16 but has an Asp at the +1 
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position. Additionally, the data suggest that a Met residue at the +1 position may decrease 
reactivity as low activity was observed with the peptides in the screen (Figure 4.1). 
Furthermore, THRAP3 has a +1 Met residue and reacts slowly with both enzyme forms.  
The +1 Met residue may interfere with local HDAC8-substrate interactions and decrease 
the stability of the enzyme-substrate complex. These data suggest that while the +1 (Z) 
and -1 (X) positions are important determinants of the metal-dependent substrate 
selectivity, the residues at other local sites also alter selectivity.  This avenue remains to 
be investigated further. 
Finally, data from the methylcoumarin labeled peptides suggests that a -1 Kac could 
present a detriment to HDAC8-catalyzed deacetylation. Both SIRT1 and HDAC8 FdL 
substrates are based on a small p53 peptide, with the only difference between the two 
being that both lysines are acetylated in the HDAC8 FdL substrate while only the terminal 
lysine adjacent to the methylcoumarin is acetylated in the SIRT1 substrate. Even though 
these peptides have the most sequence similarity, the Fe2+/Zn2+ ratios exhibit the biggest 
differential between these two peptides, with ratios of 3 and 15, respectively, for the p53 
FdL and SIRT FdL substrates. These data suggest that HDAC8-catalyzed deacetylation 
is altered by acetylation and, possibly, other PTMs, near the target acetyllysine.  
 The data presented reveal that HDAC8 substrate selectivity may depend on the 
identity of the bound divalent metal ion. Although many peptides have comparable 
reactivity with both Fe2+- and Zn2+-HDAC8, other peptides have significantly higher 
reactivity with the iron-bound enzyme. The data suggest that peptide sequence, length 
and local interactions with residues flanking the acetyl lysine moiety are synergistic in 
determining the metal-dependent selectivity of HDAC8. Furthermore, these data predict 
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that in cells either metallated form of HDAC8 has deacetylase activity and that 
manipulating the identity of the divalent metal bound could possibly alter the pool of 
reactive protein substrates. 
 Remarkably, the ratio of the Fe2+ and Zn2+-HDAC8 activities varies greatly 
depending on the sequence of the substrate peptide. Our laboratory has previously 
shown that Fe2+-HDAC8 haa a higher kcat/KM value than Zn2+-HDAC8 for a commercial 
methyl-coumarin labeled peptide15 (Table 4.1), Here we demonstrate that even for short 
6-mer peptides, which interact only with the active site and substrate binding surface 
directly near the active site, there are drastic differences in specificity based on the 
divalent metal ion. A constant Fe2+/Zn2+ ratio for all peptides tested would have suggested 
that changing the identity of the divalent metal ion was a method to modulate overall 
cellular deacetylation. However, the substrate-dependent variation in the Fe2+/Zn2+ ratio 
indicates a more complicated mechanism of regulation that involves altering both the 
activity and selectivity of HDAC8 which is predicted to lead to differential changes in 
cellular acetylation. 
 The structural basis for the metal-dependent substrate specificity remains 
undefined. Crystal structures of HDAC8 indicate that the substrate binding site is primarily 
composed of flexible loops which can accommodate a range of substrates but can also 
influence the enzyme’s specificity13,28,32–34. Furthermore, the residues that coordinate the 
active site divalent metal ion are positioned by these loops. Intrinsic properties of the 
divalent metal ion, including Lewis acidity and size, could influence the structure and 
dynamics of the loop regions and alter the binding interface presented to substrates. 
Altering the active site metal coordination is expected to propagate structural changes to 
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the peptide binding site via the residues in the hydrophobic shell around the metal 
ligands35. 
 The metal-dependent selectivity of HDAC8 may be important for regulating levels 
of acetylated proteins in the cell, particularly because relative concentrations of Zn2+ and 
Fe2+ fluctuate with changing cellular conditions20,36. For example, cellular zinc is tightly 
buffered but the concentration of exchangeable Zn2+ is increased under redox stress as 
cellular zinc ligands are oxidized and release Zn2+.37 Zn2+ concentrations can increase 
from picomolar (pM) to nanomolar levels (nM) under oxidative stress37. The dependence 
of readily exchangeable Fe2+ concentration on the redox state is unclear, likely due to the 
limits of detection and differentiation from Fe3+. We have previously shown that the metal-
dependent bacterial deacetylase LpxC binds either Zn2+ or Fe2+ in E. coli based on the 
relative abundance of these metals in the growth conditions, and that the metal cofactor 
bound to LpxC readily switches from Fe2+ to Zn2+ under aerobic conditions in vitro38.   A 
similar mechanistic model may occur for metal-dependent HDACs.  One scenario is that 
Fe2+-HDAC8 (KD = 0.2 ± 0.1 μM)21 is the predominant species under basal conditions with 
low exchangeable Zn2+ concentrations, but upon an increased exchangeable Zn2+ 
concentration, HDAC8 exchange bound Fe2+ for the higher affinity Zn2+ (KD = 5 ± 1 pM)21, 
maintaining HDAC8 activation but altering the activity level and substrate selectivity. 
 Our peptide data present a universal trend of greater catalytic efficiency for the 
Fe2+-bound enzyme among the longer, more physiologically relevant peptides and 
supports our initial screen where we saw a significant difference between peptide 
specificity for both metalloforms, These data are consistent with the hypothesis that the 
enzyme is activated, at least in part, by Fe2+ in the cell. Furthermore, it is possible that 
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the peptides with a high ratio of Fe2+/Zn2+ activity may represent in vivo substrates while 
peptides with a near stoichiometric ratio may be nonspecific substrates. This is bolstered 
by the fact that the two highest Fe2+/Zn2+ ratios (SMC3 9-mer and CSRP2BP) correspond 
to proteins recently identified as potential HDAC8 substrates in a proteomic screen11.  
Conclusions 
 Overall, this work is the first to demonstrate that the substrate selectivity of a metal-
dependent HDAC varies with the identity of the active site divalent metal ion. The SAMDI 
peptide screen enabled a broad survey of enzyme metalloform selectivity, and the 
enzyme assays in solution demonstrated a range of Fe2+/Zn2+ ratios towards substrates 
of physiological relevance. There is no direct evidence that metal switching plays an 
important regulatory role in cells.  However, our data alludes to the possibility that cellular 
conditions dictate the active site divalent metal ion and this seems to regulate 
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Conclusions and Future Directions 
Overview 
 Since the discovery of acetylation of histone tails1, the acetylome has been 
expanded and many non-histone acetylated proteins have been predicted and 
discovered2,3. Acetylation has been recognized to affect proteins in many cellular 
processes, such as cell cycle regulation, metabolism and gene expression2. With the 
ongoing expansion of the acetylome, research has focused on understanding how this 
post-translational modification is regulated. The enzymes that catalyze acetylation and 
deacetylation are the lysine acetyltransferases and histone (or acetyllysine) 
deacetylases. To date, there are 18 deacetylases that catalyzing deacetylation, 11 of 
which are metal dependent enzymes.  
 One crucial piece of information that the acetylation field is currently attempting to 
unravel is the substrate specificity of each HDAC isozyme. These data would allow  a 
better understanding of the role of each isozyme in the cell. In this thesis, I have presented 
work that improves upon the understanding of the function of HDAC8 by characterizing 
regulation by metal switching and the role that alterations in metal affinity could play in 
Cornelia de Lange spectrum disorders. Additionally, I have improved upon traditional 
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HDAC-substrate recognition methods using chemical covalent capture and discovered 
new HDAC8 substrates. Overall, these findings describe a new set of techniques that 
could be adapted for use in analyzing the function of other HDAC isozymes and, 
potentially, other enzymes that catalyze posttranslational modifications.  
Chemical Covalent Capture of HDAC8 Substrates 
 One of the most important goals in the acetylation field is to profile HDAC-specific 
substrates. This specific profiling has proven difficult due to the continuous discovery of 
new acetylated proteins, the dynamic nature of HDAC-substrate interactions and the 
reactivity of multiple HDAC isozymes with particular substrates4. Efforts to map the 
acetylome include computational modeling of acetylation3, SILAC studies along with both 
pan-HDAC and HDAC specific inhibitors4, and HDAC-eGFP fusion proteins expressed in 
mammalian cells5. Although these methods have proven useful in providing insight into 
HDAC substrates, they remain limited in identifying transient HDAC-substrate interactions 
and highlighting HDAC-specific substrates. Here, we report an improved chemical 
covalent capture method to identify transient complexes using HDAC8 as a model 
isozyme. This approach takes advantage of site specific labeling with a cross linker 
followed by mass spectrometry and proteomics to identify HDAC8 binding proteins and 
potential substrates. 
 Previous work in the Fierke laboratory demonstrated crosslinking using Bpa-
labeled Rpd3, HDAC8’s yeast ortholog. I elaborated on this concept and developed an 
HDAC8 co-immunoprecipitation and crosslinking assay using HEK293 lysate. We 
coupled this assay with LC-MS/MS, proteomics and the Flex-Pep-Bind algorithm6 to 
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predict reactive acetyl lysine residues in proteins that were covalently trapped with 
HDAC8. I then tested the highest scoring protein-based peptides using an enzyme-
coupled assay7 and demonstrated that many of the peptides tested have equal and/or 
faster deacetylation than an SMC3-based peptide, the best validated HDAC8 substrate.  
This improved approach has allowed us to identify 139 HDAC8 potential substrates 
that had not been found by any other previous techniques. We identified proteins involved 
in a variety of cellular pathways, including metabolism, DNA repair, protein folding, among 
others. Many of these putative substrates were primarily new HDAC targets but some 
have been identified in previous studies5,8. We found PFKP and TUBA1A, both identified 
as potential HDAC8 substrates by proteome chips8 and HDAC8-eGFP fusion protein 
immunoprecipitation studies5, respectively. Further studies of intact protein substrates, 
beyond peptide deacetylation, will be needed to further validate the pool of HDAC8-
specific substrates.  
Some of the most interesting HDAC8 substrates identified through crosslinking are 
heat shock protein 90-beta (HSP90AB1), ATP-citrate lyase (ACLY), integrin beta-1 
(ITGB1) and the regulator of nonsense transcripts (UFP1). I measured HDAC8-catalyzed 
deacetylation of the best scoring peptides for each of these proteins and found rate 
constants of over 100 M-1s-1.  
The next step is to further validate this approach.  One method would be to express 
and purify these proteins recombinantly using amber suppression methods to incorporate 
single, non-natural acetyl lysine residue at positions observed in cells and measure 
HDAC8-catalyzed deacetylation visualized using an anti-acetyl lysine antibody. To start 
this project, I have prepared constructs for expressing HSP90AB1 (WT and K429ac) with 
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site specific incorporation of a single acetyl lysine in E. coli and I plan to purify these 
enzymes and measure rates of deacetylation of the full-length protein substrate. 
 
 Additionally, further validation would require in vivo evidence showing an increase 
in acetylation of these proteins upon HDAC8 specific inhibition. Acetylation of cellular 
proteins before and after treatment with the inhibitor could be visualized using an anti-
acetyl lysine antibody and/or quantified using mass spectrometry. The effect of 
acetylation on the function of these proteins is currently unknown.  However, a 
comparison of the properties of the native and singly acetylated protein will begin to 
answer this question as well as provide insight into HDAC8’s role in cellular processes.  
Figure 5.1: Proposed acetylation site of HSP90B 
Full-length structure of HSP90B (PDB: 3PRY). My work has shown that a small acetylated peptide 
based on the sequence around K429 is readily deacetylated by HDAC8 (Table 2.2 and Figure 2.5A). 
Purification of HSP90B with acetylated K429 and testing HDAC8-catalyzed deacetylation will further 




We expect that further work in the Fierke laboratory will incorporate non-natural 
amino acid cross linkers into other HDAC isozymes in order to gain further knowledge of 
the acetylome as well as the specific role of each HDAC. 
However, this method still requires optimization to be carried out inside mammalian 
cells rather than in cell lysates. Protein-substrate localization is a problem when working 
with cellular lysates and some of the proteins that crosslinked to HDAC8 are proposed to 
be exclusively located in the mitochondria, a cell compartment where HDAC8 has not 
observed. Unfortunately, the main problem with incorporation of non-natural amino acids 
is the slow expression of tRNA and slow growth in mammalian cells, which decreases the 
fidelity and synthesis of the target protein. Currently, optimization of this system by 
increasing tRNA/tRNA synthetase levels in combination with engineered release factors 
(RFs) has shown promise in non-natural amino acid protein synthesis fidelity in both 
mammalian cells and E.coli9,10. We anticipate that the development of these systems will 
allow us to further optimize, incorporate and diversify our crosslinking system into 
mammalian cells in the near future.   
 
Effects of HDAC8 CdLS mutants on Catalysis 
 HDAC8’s best known biological role is the deacetylation of SMC3, a component of 
the cohesin complex11. The cohesin complex is responsible for the proper separation of 
sister chromatids during mitosis. Mutations in the genes that encode these complex 
components are responsible for the Cornelia de Lange spectrum (CdLS) disorders. It was 
recently discovered that missense mutations in the HDAC8 gene can also lead to CdLS 
110 
 
phenotypes11. These missense mutations result in partial to complete loss of deacetylase 
activity. Basic biochemical characterization of some of these mutants has been 
performed12,13 but many questions remain about how these mutations affect deacetylase 
activity. Many of these mutations are not close to the active site and are not in residues 
that are known to be involved in catalysis. In our work, we studied three mutations (P91L, 
I243N and T311M) with different effects on catalysis using multiple biochemical 
approaches.  We hypothesize that the effects of these mutations on catalytic activity could 
be attributed to small, minimal changes in the internal bonding network of HDAC8 while 
still retaining its overall secondary structure. 
 We demonstrated that although each mutant retains its overall secondary 
structure, the effects on catalysis are varied. The P91L mutant retained properties most 
similar to WT-HDAC8. The P91L mutation has been hypothesized to affect substrate 
binding by altering the positioning and flexibility of the L1 loop, decreasing peptide-
substrate affinity and increasing product release12,14,15. Our data indicates that this 
mutation has little effect on the catalytic activity with peptides (Table 3.1 and Table 3.3) 
suggesting that it does not significantly alter peptide-substrate affinity, however, it is 
possible that peptide substrate affinity does not reflect the effects on full-length protein 
substrate affinity. The T311M mutation has a larger effect on the catalytic activity and this 
mutation has been proposed to alter the internal bonding network that helps coordinate 
product release and to possibly affect substrate affinity by leading to a reorganization of 
the L1 loop14,15. Our data demonstrate that both the T311M and I243 mutations 
significantly decrease Zn2+ binding affinity while retaining Fe2+ binding affinity.  This loss 
of zinc binding affinity likely leads to loss of deacetylase activity in cells where the readily 
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exchangeable zinc concentration is in the pM range16,17.  However, it is unclear what 
structural alterations occur in the T311M mutant that specifically affect Zn2+ affinity. 
 I243N HDAC8 is the most interesting mutant to perform follow up work. This 
mutant is located near one of the monovalent ion (K+) binding sites that activates HDAC8 
in a time-dependent manner18, likely by stabilizing protein structure. We hypothesize that 
mutations near this site could either significantly decrease K+ binding to this site and 
inhibit activation or allow K+ binding that is uncoupled to enzyme activation. The 
unexpected effect of decreasing Zn2+ but not Fe2+ affinity leads to the suggestion that 
there could be multiple conformations that Fe2+ binds to with similar affinity while high 
affinity Zn2+ binding requires a specific enzyme conformation to be activated (Figure 5.2).  
 
  
Figure 5.2: Potential mechanisms of divalent metal ion binding 
Proposed mechanism of how the I243N mutation affects Fe2+ (A) and Zn2+ (B) binding and activation. 
We hypothesize that Fe2+ is capable of binding to two different enzyme forms with similar affinities, and 
that both forms possess some degree of catalytic efficiency while Zn2+ can only bind a form of the 
enzyme that is not activated. In order to probe this mechanism, we must identify the intrinsic differences 
between Fe2+ and Zn2+ bound HDAC8. 
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A future way to investigate this proposed mechanism would be to monitor 
deacetylase activity as a function of K+ concentration as well as following changes in 
secondary structure as a function of K+ concentration using circular dichroism for both 
WT and the mutants. Additionally, investigation of more CdLS mutations would provide 
insight into structural changes in HDAC8 that are important for catalysis. 
 Overall, these studies have provided insight into how HDAC8-catalyzed 
deacetylation is regulated by internal structural rearrangements.   
 
HDAC8 Substrate Specificity Regulated Through Divalent Metal Switching 
  Previous studies have shown that HDAC8 is activated by by either Fe2+ or Zn2+. 
and metal chelating inhibitors, such as suberanilohydroxamic acid (SAHA), exhibit 
efficacy towards both enzyme metalloforms15. This brings into question the identity of the 
catalytic metal ion in vivo.  HDAC deacetylase activity in mammalian and E. coli lysates, 
as well as immunopurified HDAC8 from HeLa cells, have shown oxygen sensitivity16. We 
hypothesize that based on oxidative stress and/or other cellular conditions, HDAC8 is 
capable of exchanging between Zn2+ and Fe2+, thus it could be possible for each 
metalloform to have different substrate specificities in vivo. Our data present evidence of 
metal-dependent substrate specificity through analyzing reactivity with both a high 
throughput peptide library as well as a library of peptides based on putative in vivo and 
methylcoumarin-bound substrates. We demonstrate that Fe2+-HDAC8 catalyzes 
deacetylation faster than Zn2+-HDAC8 of all but one of the substrates tested.   The ratio 
of Fe/Zn deacetylation specificity rate constants varies between 0.3 and 15. Overall, we 
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have shown that Fe2+-HDAC8 is significantly more active than Zn2+-HDAC8 under the 
conditions tested and that the metal-dependent substrate selectivity is variable. 
 Additionally, our data suggest some determinants of HDAC8 substrate specificity 
including peptide length, stabilization by aromatic residues like Tyr and Phe at the +1 and 
+3 positions and potential inhibition of deacetylation by Met residues at the +1 residues. 
These data have provided insight on peptide-substrate selectivity for HDAC8 using 
biologically relevant metals. 
 However, the sample pool that we tested was not diverse enough to provide 
statistically significant validation of these determinants. Expanding the library of peptides 
tested using more peptides based on putative substrates and strategic varying of the 
peptide sequence would allow an enhanced understanding of the HDAC8 substrate 
selectivity. Additionally, HDAC8 reactivity could be altered by posttranslational 
modifications, particularly at the +1, -1 and +3 positions.  This proposal could be tested 
by measuring reactivity of HDAC8 with peptides containing acetyl lysine, methyl lysine 
and/or phosphorylated residues at these sites. This would provide context into how other 
post-translational modifications affect acetylation in a direct manner. 
 Finally, a remaining question about HDAC8 substrate selectivity is the site(s) of 
additional interactions with full-length protein substrates that alter binding affinity relative 
to peptides. There are likely additional both positive and negative interactions, such as 
site flexibility, with proteins that alter selectivity relative to peptides. Despite this, our data 
clearly demonstrate that HDAC8 selectivity is altered depending on the identity of the 
active site metal ion. Investigating HDAC8 reactivity using full-length substrates will also 
examine how HDAC8 recognizes protein substrates based on the divalent metal bound. 
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 Overall, our work demonstrates that peptide-substrate specificity of HDAC8 
depends on the identity of the active site divalent metal ion. Our enzyme-coupled assays 
using physiologically relevant peptide substrates provide insight into the HDAC8’s 
substrate recognition system. Understanding this specificity will provide avenues for 


















 The HDAC field is at an interesting crossroad where we are starting to understand 
what biological roles each isozyme plays in the cell. Particularly with HDAC8, great strides 
have been made to identify protein substrates and understand enzyme reactivity. The 
deacetylase field has acquired a lot of interest from the scientific community in recent 
years. More importantly, with the discovery of HDAC8’s role in the Cornelia de Lange 
spectrum disorders, we have evidence of a disease in which HDAC8-catalyzed 
deacetylation plays an essential role in development. In the work presented here, we have 
made exciting breakthroughs, like the development of an improved HDAC8 co-
immunoprecipitation approach along with the discovery of new HDAC8 substrates. The 
techniques described in this thesis will provide new tools to discover HDAC-specific 
substrates, understand how HDACs select their substrates in vivo and, in the nearby 
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SYAC 24.311 0.024 2 Putative HDAC8 substrate 
MCMBP 22.468 0.143 1 
 
GSTO1 18.313 0.264 2 
 
RADI 12.529 0.280 16 
 
SNX5 12.175 0.252 2 
 
T2FA 11.600 0.066 2 
 
FHL1 10.286 0.022 1 
 
GEMI 7.487 0.235 1 
 
PGAM4 7.266 0.027 5 
 
VIGLN 7.088 0.052 4 
 
H90B3 6.968 0.092 35 
 
H2BFM 6.941 0.188 1 
 
1433G 6.420 0.425 4 
 
TBA1A 5.206 0.063 56 Observed as an HDAC8 substrate 
IF4B 5.189 0.110 3 
 
SYEP 5.163 0.016 4 
 
H14 4.968 0.017 5 Putative HDAC8 substrate 
K1C9 4.770 0.015 30 
 
HNRPM 4.731 0.048 1 
 
SC24C 4.723 0.070 5 Putative HDAC8 substrate 
COPA 4.577 0.020 8 Putative HDAC8 substrate 
SYQ 4.544 0.022 2 
 
LDH6B 4.536 0.124 2 
 
ACTBL 4.271 0.051 26 
 
LARP1 4.254 0.037 4 Putative HDAC8 substrate 
PDLI1 4.206 0.031 3 Putative HDAC8 substrate 
ACTN2 4.191 0.032 11 
 
XRN2 4.175 0.030 1 
 
DHX9 4.158 0.024 5 
 
RL7A 4.131 0.050 10 
 
ESYT1 4.095 0.036 6 
 




HSP72 4.065 0.027 53 
 
PSA 4.031 0.039 23 Putative HDAC8 substrate 
ITB1 4.025 0.038 7 Putative HDAC8 substrate 
CAPR1 4.002 0.033 5 
 
LRC47 3.976 0.047 2 
 
IF4G1 3.970 0.063 13 
 
DCTN2 3.961 0.117 7 
 
MSH2 3.960 0.036 3 Putative HDAC8 substrate 
PGTB1 3.955 0.075 4 
 
TIF1B 3.939 0.036 21 Binds NuRD complex (HDACs) reference 
CDK1 3.937 0.052 5 
 
EIF3B 3.929 0.027 7 Putative HDAC8 substrate (Eric Sullivan 
thesis) 
VPS35 3.924 0.026 4 
 
ACTN3 3.909 0.140 9 
 
UBA1 3.879 0.036 46 
 
PGAM1 3.875 0.133 9 
 
DPP3 3.779 0.027 9 
 
RENT1 3.766 0.026 10 Putative HDAC8 substrate 
HS90B 3.758 0.037 87 Putative HDAC8 substrate 
SFPQ 3.757 0.035 13 Putative HDAC8 substrate 
ACTN1 3.736 0.021 16 Putative HDAC8 substrate 
ENPL 3.724 0.038 51 
 
PFKAP 3.720 0.053 3 Putative HDAC8 substrate 
E41L2 3.718 0.032 1 
 
KINH 3.713 0.027 19 Putative HDAC8 substrate 
SF3B2 3.704 0.125 1 
 
C1TC 3.704 0.033 36 
 
HNRL1 3.702 0.040 2 
 
UGDH 3.695 0.021 1 
 
RBBP7 3.662 0.045 4 
 
MCM6 3.649 0.042 10 
 
PARP1 3.639 0.031 32 
 
UBP5 3.623 0.052 5 
 
EZRI 3.622 0.030 26 
 
HS105 3.619 0.033 19 
 
PSMD2 3.616 0.034 8 
 
TPIS 3.609 0.026 21 
 
MSH6 3.600 0.202 1 Putative HDAC8 substrate (Noah Wolfson 
thesis) 
CLH1 3.597 0.027 45 
 
ACLY 3.584 0.036 20 Putative HDAC8 substrate 
120 
 
BASI 3.573 0.131 2 
 
GANAB 3.562 0.031 27 
 
P5CS 3.556 0.037 11 
 
EIF3C 3.528 0.045 9 
 
AT1A1 3.508 0.034 19 
 
CAND1 3.507 0.026 24 
 
DDB1 3.484 0.028 5 
 
CPSF6 3.477 0.021 6 
 
CSDE1 3.473 0.033 5 
 
HSPB1 3.462 0.060 3 
 
RNH2A 3.461 0.046 1 
 
1433B 3.456 0.065 10 
 
IPO7 3.451 0.027 3 
 
PSD12 3.451 0.020 5 
 
ACON 3.440 0.048 3 
 
ACTN4 3.422 0.032 35 
 
DBNL 3.403 0.178 5 
 
EF2 3.402 0.040 93 
 
HNRPU 3.396 0.045 22 
 




3.382 0.048 59 
 
TERA 3.380 0.044 34 
 
HXK1 3.367 0.026 6 
 
AINX 3.361 0.044 3 
 
XRCC5 3.359 0.033 20 
 
STRAP 3.343 0.047 4 
 
TNPO1 3.340 0.043 8 
 
PRS6B 3.332 0.147 2 
 
SAE2 3.324 0.036 4 
 
MCM7 3.319 0.030 12 
 
SND1 3.314 0.042 17 
 
VINC 3.299 0.034 40 
 
GLRX3 3.267 0.028 11 
 
HS90A 3.266 0.037 92 Putative HDAC8 substrate 
GLU2B 3.261 0.056 9 
 
GBLP 3.253 0.070 6 
 
LAP2B 3.252 0.042 8 
 
MYH9 3.248 0.028 63 
 
CAN1 3.242 0.070 2 
 
MYH14 3.234 0.044 16 
 




MCM5 3.201 0.036 11 
 
VDAC1 3.194 0.029 10 Putative HDAC8 substrate 
ANM1 3.192 0.089 3 
 
PRS6A 3.181 0.194 3 
 
ACOT9 3.169 0.026 7 
 
SF01 3.148 0.028 7 
 
DHX15 3.140 0.041 6 
 
STX11 3.137 0.029 4 
 
MIC60 3.129 0.038 8 
 
CPNE3 3.127 0.051 12 Observed as an HDAC8 substrate 
IPYR 3.127 0.039 6 
 
DHE3 3.123 0.032 12 
 
COPG1 3.104 0.044 8 
 
AXA2L 3.099 0.052 21 
 
2-Sep 3.072 0.120 3 
 
U5S1 3.070 0.043 18 
 
PDIP2 3.052 0.029 2 
 
EF1B 3.050 0.045 2 
 
NUCL 3.044 0.043 43 
 
IPO5 3.020 0.079 5 
 
HSP7C 3.019 0.050 91 
 
AIP 3.017 0.040 3 
 
DDX17 3.009 0.040 29 
 
FUBP3 2.997 0.052 3 
 
RIR1 2.996 0.037 10 
 
FUS 2.954 0.047 5 
 
PRDX1 2.905 0.040 4 
 
UBQL1 2.880 0.046 2 
 
IF2B3 2.874 0.120 4 
 
ALDOC 2.869 0.068 2 
 
NSUN2 2.868 0.033 9 
 
FUBP1 2.854 0.035 13 
 
RL5 2.853 0.123 11 
 
IMB1 2.852 0.044 25 
 
PHB2 2.843 0.032 18 
 
GTF2I 2.817 0.048 1 
 
G0S2 2.806 0.074 2 
 
ACTZ 2.804 0.012 5 
 
RUVB2 2.784 0.079 12 
 
ROA1 2.776 0.046 7 
 




EIF3A 2.740 0.044 24 
 
STAU1 2.732 0.049 4 
 
PYGL 2.720 0.044 8 
 
FEN1 2.706 0.081 3 
 
FETUA 2.701 0.043 8 
 
SEPT9 2.688 0.037 5 
 
G3PT 2.679 0.000 2 
 
PABP4 2.675 0.060 13 
 
HSP74 2.672 0.044 22 
 
NDUS1 2.664 0.169 2 
 
PCBP1 2.662 0.035 11 
 
NYNRI 2.659 0.066 1 
 
GFAP 2.655 0.126 4 
 
RL4 2.633 0.154 31 
 
GDIA 2.633 0.043 11 
 
CORO7 2.630 0.070 3 
 
DNM1L 2.628 0.084 4 
 
HNRH1 2.616 0.063 9 
 
SRSF7 2.615 0.030 2 
 
MCM3 2.613 0.057 12 
 
OST48 2.608 0.231 5 
 
ALBU 2.604 0.052 33 
 
RL8 2.595 0.048 15 
 
BACH 2.595 0.035 4 
 
HMGB2 2.594 0.212 5 
 
7-Sep 2.593 0.051 7 
 
METK2 2.589 0.141 4 
 
KAD2 2.587 0.192 4 
 
MCM4 2.579 0.072 11 
 
ANXA2 2.570 0.040 25 
 
STML2 2.550 0.189 3 
 
GRP78 2.548 0.065 53 
 
HS74L 2.547 0.046 10 
 
LDHC 2.544 0.044 3 
 
PSMD1 2.542 0.058 7 
 
PRS10 2.539 0.027 3 
 
SYMC 2.539 0.062 9 
 
STIP1 2.530 0.056 35 
 
SF3B3 2.528 0.087 7 
 
SNX2 2.525 0.142 4 
 




ATPB 2.522 0.206 27 
 
KCRB 2.504 0.035 15 
 
TBB2A 2.503 0.040 55 
 
LKHA4 2.493 0.048 3 
 
COPB 2.481 0.089 10 
 
QCR1 2.475 0.060 1 
 
RBM39 2.469 0.079 2 
 
IQGA1 2.468 0.062 12 
 
BIEA 2.457 0.139 3 
 
CHM4B 2.453 0.043 2 
 
1433T 2.450 0.444 8 
 
MPCP 2.447 0.047 8 
 
PLST 2.436 0.063 43 
 
KPYM 2.427 0.072 57 
 
PUF60 2.425 0.063 3 
 
ANXA5 2.418 0.057 17 
 
LA 2.409 0.181 3 
 
SET 2.403 0.034 12 
 
ATP4A 2.398 0.065 2 
 
RL6 2.392 0.043 18 
 
XPO2 2.390 0.049 28 
 
TRFL 2.383 0.099 1 
 
RFA1 2.382 0.090 4 
 
PYRG1 2.361 0.060 2 
 
CNDP2 2.356 0.251 2 
 
ENOA 2.340 0.197 70 
 
K22O 2.331 0.071 17 
 
TKT 2.321 0.069 28 
 
UBP14 2.319 0.112 3 
 
PUR2 2.317 0.050 9 
 
PABP1 2.311 0.069 28 
 
PHB 2.308 0.061 8 
 
MYH10 2.296 0.072 31 
 
NP1L4 2.285 0.078 7 
 
XRCC6 2.266 0.084 22 
 
SMC2 2.265 0.079 5 Sequence similarity with SMC3 (25%) 
SRSF6 2.261 0.086 3 
 
TPM3 2.255 0.277 2 Observed as an HDAC8 substrate 
HNRPF 2.255 0.209 10 
 
YBOX3 2.252 0.087 6 
 




BLMH 2.245 0.059 2 
 
PDIA4 2.242 0.077 16 
 
YBOX1 2.232 0.280 5 
 
RS3 2.226 0.078 11 
 
DLDH 2.218 0.191 2 
 
RPN1 2.217 0.077 15 
 
TXND5 2.197 0.082 5 Observed as an HDAC8 substrate 
IMA1 2.195 0.103 7 
 
PAIRB 2.193 0.068 9 
 
DDX3X 2.179 0.071 13 
 
TCPQ 2.174 0.081 39 
 
SYRC 2.171 0.098 1 
 
RS8 2.158 0.357 5 
 
KATL2 2.154 0.078 4 
 
IF2G 2.153 0.136 9 
 
VAT1 2.144 0.097 3 
 
FUBP2 2.131 0.100 32 
 
KTN1 2.126 0.086 6 
 
CH60 2.124 0.095 51 
 
PRDX4 2.124 0.296 4 Putative HDAC8 substrate (Eric Sullivan 
thesis) 
TCPH 2.119 0.095 22 
 
SRC8 2.115 0.074 10 
 
DDX5 2.112 0.131 16 
 
2AAA 2.104 0.083 20 
 
TCPE 2.102 0.098 23 
 
TCPG 2.100 0.097 21 
 
LMNA 2.096 0.089 3 
 
TRAP1 2.093 0.109 19 
 
RS4X 2.091 0.423 7 
 
ADT3 2.089 0.088 9 
 
FKBP4 2.086 0.077 29 
 
NONO 2.082 0.082 14 
 
PRDX2 2.079 0.079 3 
 
IF2B1 2.077 0.095 19 
 
CALX 2.070 0.162 15 
 
RL13 2.062 0.105 8 
 
EF1D 2.045 0.014 16 
 
IF4A1 2.043 0.256 33 
 
ROA2 2.040 0.119 7 
 
SAM15 2.033 0.091 5 
 




RS6 2.027 0.066 8 
 
NPM 2.023 0.075 7 
 
SGT1 2.015 0.198 4 
 
EWS 2.010 0.090 3 
 
OLA1 2.008 0.088 2 
 
OAT 1.992 0.100 7 
 
LDHA 1.983 0.029 27 
 
TBB3 1.978 0.361 33 
 
PABP3 1.973 0.072 13 
 
IF2A 1.971 0.167 3 
 
EIF3I 1.970 0.088 3 
 
PYGM 1.966 0.168 7 
 
IF4H 1.965 0.089 5 
 
HNRPR 1.957 0.265 2 
 
F10A1 1.957 0.116 7 
 
G3P 1.950 0.017 33 
 
TCPD 1.949 0.123 26 
 
PDIA3 1.939 0.119 32 
 
APEX1 1.934 0.156 4 
 
HNRPQ 1.928 0.150 10 
 
HCN3 1.926 0.128 2 
 
RD23B 1.925 0.102 7 
 
RCN1 1.911 0.283 4 
 
PGK1 1.908 0.110 24 
 
AT1A2 1.898 0.075 13 
 
ILF2 1.882 0.221 3 
 
G3BP1 1.879 0.168 8 
 
NASP 1.867 0.066 25 
 
TCPZ 1.865 0.122 22 
 
IF2B2 1.855 0.153 5 
 
ANXA1 1.851 0.082 20 
 
GUAA 1.841 0.181 2 
 
RSSA 1.835 0.064 12 
 
SYTC 1.830 0.126 15 
 
LSR 1.825 0.037 4 
 
PIPNA 1.816 0.127 2 
 
RUVB1 1.813 0.132 9 
 
UCHL1 1.806 0.554 6 
 
ALDOA 1.795 0.018 28 
 
MYH11 1.793 0.145 14 
 




RTCB 1.789 0.137 5 
 
RAB1C 1.782 0.191 2 
 
PRDX6 1.780 0.143 7 
 
LMAN1 1.775 0.176 5 
 
NMT1 1.775 0.176 2 
 
PDIA6 1.767 0.335 14 
 
EIF3D 1.764 0.286 3 
 
6PGD 1.759 0.165 11 
 
NO66 1.759 0.328 4 
 
ANXA6 1.758 0.246 6 
 
RLA0 1.758 0.405 11 
 
IF4A3 1.751 0.116 11 
 
EMD 1.748 0.093 4 
 
PAP1L 1.747 0.184 7 
 
TBB6 1.741 0.411 27 
 
CISY 1.738 0.135 18 
 
EIF2A 1.735 0.319 1 Putative HDAC8 substrate (Eric Sullivan 
thesis) 
API5 1.733 0.217 4 
 
SERA 1.732 0.197 13 
 
CAP1 1.722 0.155 10 
 
IMDH2 1.721 0.204 12 
 
RAB1B 1.700 0.356 2 
 
ACTBM 1.699 0.173 10 
 
RINI 1.697 0.196 3 
 
PSD13 1.675 0.347 4 
 
GDIB 1.672 0.239 11 
 
ILF3 1.671 0.260 6 
 
PSMD4 1.668 0.090 6 
 
SMC1A 1.666 0.227 3 Observed as an HDAC8 substrate 
RL3 1.658 0.178 15 
 
HNRH2 1.652 0.394 6 
 
TADBP 1.648 0.073 4 
 
DDX6 1.642 0.282 3 
 
SSRP1 1.639 0.197 9 
 
TAGL2 1.620 0.302 3 
 
SYHC 1.620 0.590 4 
 
PDIA1 1.611 0.211 33 Putative HDAC8 substrate (Eric Sullivan 
thesis) 
TCPB 1.606 0.220 33 
 
NACAM 1.603 0.203 19 
 




PAK2 1.587 0.224 6 
 
PRS4 1.570 0.271 7 
 
DDX1 1.567 0.514 4 
 
ENOG 1.561 0.277 8 
 
WDR1 1.553 0.370 6 
 
UBP7 1.546 0.261 2 
 
LDHB 1.530 0.044 28 
 
C1QBP 1.521 0.542 4 
 
THIL 1.519 0.157 10 
 
G6PI 1.518 0.354 21 
 
CL054 1.517 0.454 1 
 
CLIC1 1.507 0.303 7 
 
AT1A3 1.495 0.422 9 
 
HMCS1 1.494 0.359 6 
 
EIF3F 1.492 0.303 2 
 
LRC59 1.488 0.398 4 
 
NDE1 1.479 0.305 3 
 
TBB5 1.478 0.524 62 
 
VATB2 1.477 0.374 8 
 
KPYR 1.473 0.300 8 
 
EF1G 1.465 0.257 28 
 
NP1L1 1.459 0.402 8 
 
HS905 1.456 0.634 17 
 
PLSI 1.450 0.205 14 
 
PSMD3 1.446 0.461 10 
 
RPR1B 1.446 0.506 2 
 
GSHR 1.438 0.501 5 
 
VDAC2 1.434 0.169 8 
 
PTBP1 1.434 0.434 9 
 
LS14B 1.420 0.669 1 
 
IF4A2 1.419 0.369 17 
 
PUR9 1.408 0.333 14 
 
ERF1 1.404 0.578 2 
 
EIF3L 1.403 0.532 1 
 
1433Z 1.398 0.440 10 
 
BASP1 1.388 0.458 8 
 
ANX11 1.386 0.446 7 
 
CAZA1 1.380 0.315 3 
 
RAN 1.378 0.614 2 
 
TCPA 1.376 0.445 22 
 




HNRPK 1.365 0.468 24 
 
4F2 1.344 0.423 4 
 
ETFA 1.332 0.659 4 
 
AATM 1.331 0.251 7 
 
SAHH 1.308 0.384 17 
 
TALDO 1.303 0.289 17 
 
TPM4 1.290 0.451 3 Observed as an HDAC8 substrate 
M3K14 1.286 0.336 6 
 
PDCD4 1.277 0.683 3 
 
COPD 1.258 0.613 1 
 
GLYM 1.253 0.630 12 
 
SFXN1 1.245 0.551 2 
 
1433E 1.239 0.611 17 
 
PSA1 1.239 0.567 6 
 
HNRPC 1.232 0.583 3 
 
RPAP3 1.231 0.444 3 
 
PSPC1 1.225 0.729 3 
 
PUR1 1.221 0.641 2 
 
MCM2 1.191 0.791 6 
 
TBB4B 1.184 0.758 64 
 
AL7A1 1.181 0.739 7 
 
MDHM 1.167 0.414 15 
 
HMGB1 1.163 0.694 9 
 
1433F 1.155 0.771 6 
 
GSTP1 1.138 0.819 6 
 
RL7 1.131 0.715 12 
 
AMPL 1.111 0.859 5 
 
2ABA 1.110 0.829 4 Observed as an HDAC8 substrate 
MARCS 1.102 0.868 3 
 
SERPH 1.100 0.855 15 
 
DPOD1 1.083 0.860 1 
 
FSCN1 1.042 0.933 11 
 
RANG 1.035 0.860 2 
 
OTUB1 1.030 0.933 7 
 
PCNA 1.027 0.872 13 
 
TBA1C 1.018 0.985 55 
 
PRP19 1.002 0.997 7 
 
HS71L 0.996 0.991 61 Putative HDAC8 substrate (Eric Sullivan 
thesis) 
CTCFL 0.983 0.963 7 
 
HDAC8 0.969 0.876 207 HDAC8 control 




ATPA 0.949 0.913 27 
 
ENOB 0.920 0.839 13 
 
RS3A 0.920 0.765 21 
 
ALDOB 0.916 0.909 3 
 
MDHC 0.912 0.788 10 
 
RPN2 0.909 0.820 4 
 
EFHD1 0.906 0.849 1 
 
HNRPD 0.883 0.783 4 
 
RL10A 0.871 0.858 3 
 
EIF3G 0.869 0.706 2 
 
MARE1 0.866 0.838 4 
 
SYDC 0.862 0.797 4 
 
NUDC 0.847 0.707 8 
 
U2AF2 0.832 0.899 1 
 
RL19 0.774 0.567 3 
 
RS2 0.759 0.524 8 
 
RL13A 0.749 0.431 1 
 
HPTR 0.743 0.661 2 
 
CALR 0.727 0.503 12 
 
GBB4 0.685 0.208 2 
 
SNX1 0.683 0.694 2 
 
SPEE 0.675 0.226 3 
 
INO1 0.669 0.603 1 
 
RCC2 0.660 0.358 11 
 
AT1B3 0.653 0.516 1 
 
RAB14 0.628 0.350 4 
 
PUR6 0.626 0.344 11 
 
STRA8 0.621 0.343 1 
 
SCMC1 0.614 0.302 1 
 
LDH6A 0.610 0.035 5 
 
UBXN1 0.580 0.445 1 
 
ENPLL 0.532 0.389 8 
 
ACTY 0.531 0.089 3 
 
POTEI 0.518 0.418 30 
 
NSF1C 0.491 0.254 4 
 
CPSF5 0.474 0.416 1 
 
TBB2B 0.430 0.112 54 
 
FKBP3 0.422 0.112 3 
 
EF1A2 0.340 0.172 31 Sequence similarity with EF1A1 (96%) 
CBR1 0.331 0.065 2 
 




EFTU 0.278 0.175 10 
 
PCBP2 0.268 0.082 9 
 
AL9A1 0.239 0.102 2 
 
RL14 0.196 0.053 3 
 
MAOM 0.196 0.220 1 
 
RL15 0.173 0.078 1 
 
1433S 0.010 0.059 4 
 
PSA5 0.009 0.139 2 
 
PLSL 0.001 0.084 10 
 
RL18 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
TBA4A 0.000 0.000 36 Undefined due to zero unique peptides and 
overflow abundance* 
TBA8 0.000 0.000 21 Undefined due to zero unique peptides and 
overflow abundance* 
KIF5C 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
EIFCL 0.000 0.000 6 Undefined due to zero unique peptides and 
overflow abundance* 
IMDH1 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
TBA3E 0.000 0.000 35 Undefined due to zero unique peptides and 
overflow abundance* 
K1C12 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
TBA3C 0.000 0.000 44 Undefined due to zero unique peptides and 
overflow abundance* 
RS4Y2 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
TBA1B 0.000 0.000 57 Undefined due to zero unique peptides and 
overflow abundance* 
LMNB1 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
PSD11 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
EF1A3 0.000 0.000 50 Undefined due to zero unique peptides and 
overflow abundance* 
ACTA 0.000 0.000 58 Undefined due to zero unique peptides and 
overflow abundance* 
ACTC 0.000 0.000 59 Undefined due to zero unique peptides and 
overflow abundance* 
EF1A1 0.000 0.000 51 Putative HDAC8 substrate (Noah Wolfson 
thesis) 
TBB1 0.000 0.000 9 Undefined due to zero unique peptides and 
overflow abundance* 
TXNL1 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
NACA 0.000 0.000 5 Undefined due to zero unique peptides and 
overflow abundance* 




HSP77 0.000 0.000 25 Undefined due to zero unique peptides and 
overflow abundance* 
KIF5A 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
SYVC 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
ACTH 0.000 0.000 58 Undefined due to zero unique peptides and 
overflow abundance* 
ACTS 0.000 0.000 58 Undefined due to zero unique peptides and 
overflow abundance* 
IF2P 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
DHE4 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
RAB10 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
RS27A 0.000 0.000 12 Undefined due to zero unique peptides and 
overflow abundance* 
UBC 0.000 0.000 12 Undefined due to zero unique peptides and 
overflow abundance* 
K2C7 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
K2C75 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
CDK3 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
CDK2 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
POTEJ 0.000 0.000 27 Undefined due to zero unique peptides and 
overflow abundance* 
CSK21 0.000 0.000 1 Observed as an HDAC8 substrate 
K1C27 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
IDH3A 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
CSK23 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
PGAM2 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
HSP76 0.000 0.000 48 Undefined due to zero unique peptides and 
overflow abundance* 
RBBP4 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
FKBP8 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
HS71A 0.000 0.000 123 Undefined due to zero unique peptides and 
overflow abundance* 
HS71B 0.000 0.000 123 Undefined due to zero unique peptides and 
overflow abundance* 
SYNC 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 




KRT85 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
PAP1M 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
RL40 0.000 0.000 12 Undefined due to zero unique peptides and 
overflow abundance* 
ACTB 0.000 0.000 79 Undefined due to zero unique peptides and 
overflow abundance* 
ACTG 0.000 0.000 79 Undefined due to zero unique peptides and 
overflow abundance* 
AT2A2 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
H90B4 0.000 0.000 16 Undefined due to zero unique peptides and 
overflow abundance* 
GSHB 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
K2C3 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
K1C24 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
SETLP 0.000 0.000 10 Undefined due to zero unique peptides and 
overflow abundance* 
DX39B 0.000 0.000 8 Undefined due to zero unique peptides and 
overflow abundance* 
CTCF 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
HS904 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
ESTD 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
PP2AB 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
TBAL3 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
HV317 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
KRT36 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
PGK2 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
K1H1 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
DDX3Y 0.000 0.000 7 Undefined due to zero unique peptides and 
overflow abundance* 
UBQL4 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
PSAL 0.000 0.000 11 Undefined due to zero unique peptides and 
overflow abundance* 
DPYL2 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
KT33B 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 




H12 0.000 0.000 5 Undefined due to zero unique peptides and 
overflow abundance* 
KRT37 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
H13 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
RA1L2 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
HAT1 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
HS902 0.000 0.000 11 Undefined due to zero unique peptides and 
overflow abundance* 
POTEF 0.000 0.000 31 Undefined due to zero unique peptides and 
overflow abundance* 
POTEE 0.000 0.000 36 Undefined due to zero unique peptides and 
overflow abundance* 
TBB4A 0.000 0.000 49 Undefined due to zero unique peptides and 
overflow abundance* 
TCPW 0.000 0.000 7 Undefined due to zero unique peptides and 
overflow abundance* 
PCBP3 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
LAP2A 0.000 0.000 8 Undefined due to zero unique peptides and 
overflow abundance* 
PABP5 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
RS4Y1 0.000 0.000 5 Undefined due to zero unique peptides and 
overflow abundance* 
IF2GL 0.000 0.000 5 Undefined due to zero unique peptides and 
overflow abundance* 
TBB8L 0.000 0.000 23 Undefined due to zero unique peptides and 
overflow abundance* 
TBB8 0.000 0.000 25 Undefined due to zero unique peptides and 
overflow abundance* 
ZYX 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
F10A5 0.000 0.000 2 Undefined due to zero unique peptides and 
overflow abundance* 
ADT1 0.000 0.000 6 Undefined due to zero unique peptides and 
overflow abundance* 
GBB1 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
GBB2 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
RAGP1 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
ANR66 0.000 0.000 1 Undefined due to zero unique peptides and 
overflow abundance* 
TBA4B 0.000 0.000 3 Undefined due to zero unique peptides and 
overflow abundance* 
K2C6A 0.000 0.000 19 Undefined due to zero unique peptides and 
overflow abundance* 




ST134 0.000 0.000 5 Undefined due to zero unique peptides and 
overflow abundance* 
K2C8 0.000 0.000 5 Undefined due to zero unique peptides and 
overflow abundance* 
AATC 0.000 0.000 2 Putative HDAC11 substrate (Eric Sullivan 
thesis) 
ADT4 0.000 0.000 4 Undefined due to zero unique peptides and 
overflow abundance* 
PYGB 0.000 0.000 7 Undefined due to zero unique peptides and 
overflow abundance* 
GDIR1 0.000 0.000 1 
 
K1C26 0.000 0.012 3 Undefined due to zero unique peptides and 
overflow abundance* 
RS7 0.000 0.126 1 
 
RLA0L 0.000 0.347 9 Undefined due to zero unique peptides and 
overflow abundance* 
 
Table A1.2 - Proteins identified through HDAC8 covalent capture - I94 





TDRP 45.413 0.000 1 
 
HUS1B 39.205 0.001 2 
 
ADT1 10.596 0.002 7 Putative HDAC8 substrate 
S10A9 5.431 0.001 5 Tested peptide 
TXLNA 5.421 0.002 4 
 
VDAC1;VDAC3 5.178 0.001 6 Putative HDAC8 substrate 
HS71L 3.914 0.007 5 Tested peptide 
COX41 3.654 0.032 2 Tested peptide 
RL3 3.486 0.003 18 Tested peptide 
PHB 2.678 0.040 10 Tested peptide 
PLMN 2.664 0.005 5 
 
HBA 2.542 0.017 1 
 
RRAS 2.350 0.006 1 
 
HS90B;HS902 2.345 0.006 16 Putative HDAC8 substrate 
AGO1;AGO4 2.306 0.002 20 
 
LR10B 2.244 0.010 7 
 
TIF1B 2.186 0.010 15 
 
CD3E 2.165 0.091 1 
 
BRCC3 2.061 0.025 1 
 
CALM 2.049 0.045 3 
 
ANXA7 2.034 0.115 2 
 
MATR3 2.023 0.012 16 
 
MRGBP 2.014 0.020 1 
 
PZP 1.972 0.060 1 
 




ROA3 1.944 0.035 13 
 
HSP76 1.924 0.010 8 
 
HSP72 1.921 0.012 8 
 
RL29 1.887 0.116 7 
 
KHDR1 1.882 0.047 5 
 
LAP2A 1.854 0.072 10 
 
RL26L 1.841 0.081 9 
 
HS90A 1.830 0.028 9 
 
TADBP 1.818 0.062 6 
 
LMNA 1.812 0.019 29 
 
HNRL1 1.806 0.007 5 
 
AIMP2 1.795 0.057 4 
 
RL4 1.794 0.063 28 
 
KRT85 1.790 0.138 4 
 
HV309;HV312 1.786 0.023 3 
 
SRSF9 1.782 0.019 5 
 
RL13A;R13AX 1.768 0.104 5 
 
ANX11 1.756 0.085 8 
 
THOC4 1.730 0.028 1 
 
POTEI;POTEJ 1.725 0.027 20 
 
WFD12 1.723 0.049 1 
 
MUCB;IGHM 1.721 0.048 2 
 
RL21 1.707 0.034 3 
 
K2C7 1.703 0.076 26 
 
HNRPR 1.699 0.041 20 
 
CDK1 1.679 0.101 10 
 
DAZP1 1.678 0.079 1 
 
H2BFS;H2B1A 1.676 0.059 14 
 
H2B2E;H2B1B 1.676 0.059 13 
 
PERI 1.671 0.027 16 
 
ACTBM 1.660 0.051 9 
 
RL15 1.657 0.079 11 
 
ADT2;ADT3 1.651 0.063 14 
 
ML12A;ML12B 1.650 0.049 1 
 
Z280A 1.647 0.097 1 
 
RAB3B 1.640 0.125 1 
 
HNRL2 1.632 0.199 12 
 
K1H1 1.632 0.117 11 
 
RS9 1.626 0.059 16 
 
RL30 1.618 0.007 3 
 




TIA1 1.604 0.005 5 
 
RL19 1.603 0.027 3 
 
EF1A1;EF1A2 1.602 0.126 9 
 
RMXL2 1.602 0.070 7 
 
RL7 1.599 0.056 11 
 
RS13 1.592 0.062 10 
 
K2C73 1.582 0.095 17 
 
TRAP1 1.580 0.048 5 
 
IMMT 1.578 0.030 17 
 
RL14 1.574 0.077 7 
 
LMNB2 1.573 0.108 48 
 
RUVB2 1.565 0.115 9 
 
LMNB1 1.554 0.087 79 
 
HNRPC 1.550 0.057 10 
 
RL32 1.537 0.019 7 
 
HNRH1 1.533 0.091 22 
 
HNRH2 1.533 0.091 18 
 
RAB25 1.531 0.110 2 
 
ROAA 1.531 0.136 7 
 
RL22 1.525 0.078 3 
 
RL28 1.515 0.075 14 
 
DDX3X 1.515 0.002 9 
 
RS25 1.514 0.072 5 
 
FUBP2 1.512 0.152 13 
 
RL8 1.509 0.083 19 
 
RL9 1.505 0.092 2 
 
HNRPU 1.496 0.143 38 
 
POTEE;POTEF 1.493 0.159 25 
 
NOSIP 1.492 0.235 1 
 
RS15A 1.489 0.008 6 
 
PIPNA 1.489 0.111 1 
 
RS8 1.489 0.107 17 
 
RL18 1.487 0.143 9 
 
RB39A 1.485 0.133 2 
 
K1C9 1.482 0.109 42 
 
HSP71;HSP77 1.481 0.176 9 
 
KRT35 1.476 0.041 13 
 
ADH1_YEAST 1.476 0.169 69 
 
RS17L;RS17 1.475 0.046 2 
 
RBM39 1.475 0.001 4 
 




K2C3 1.469 0.135 28 
 
HNRCL 1.468 0.076 8 
 
H4 1.467 0.060 13 
 
RS26 1.464 0.130 2 
 
ACTA;ACTC 1.463 0.093 30 
 
RALY;RALYL 1.462 0.119 12 
 
RL11 1.460 0.094 6 
 
RL18A 1.460 0.154 11 
 
DHX9 1.459 0.068 32 
 
RS6 1.457 0.016 8 
 
NFM 1.456 0.062 16 
 
RL36 1.444 0.023 4 
 
DESM 1.442 0.067 29 
 
ROA2 1.440 0.148 32 
 
HDA11 1.437 0.157 20 
 
RLA2 1.435 0.093 4 
 
ODP2 1.425 0.041 3 
 
RL34 1.422 0.039 4 
 
SRSF6;SRSF4 1.418 0.114 8 
 
ILF3 1.415 0.203 11 
 
CCD73 1.414 0.217 27 
 
H1X 1.413 0.005 10 
 
HNRH3 1.413 0.154 17 
 
ACTB;ACTG 1.412 0.118 40 
 
VDAC2 1.411 0.326 8 
 
AINX 1.410 0.143 15 
 
K2C4 1.405 0.206 24 
 
HNRPK 1.404 0.078 16 
 
IF2B3 1.399 0.117 6 
 
K1C17 1.399 0.105 34 
 
HNRPD 1.397 0.187 12 
 
KRT84;KRT86 1.394 0.090 26 
 
K2C1 1.393 0.197 75 
 
AGO3 1.390 0.215 13 
 
PHB2 1.390 0.247 5 
 
LRC36 1.388 0.232 3 
 
RS11 1.387 0.057 11 
 
CO1A1 1.381 0.213 22 
 
K1C19;KT222 1.381 0.091 54 
 
RL10 1.379 0.042 13 
 




RA1L2 1.372 0.013 17 
 
S10A8 1.368 0.171 3 
 
SKIL 1.368 0.032 5 
 
SYRC 1.366 0.116 4 
 
NEDD1 1.365 0.201 3 
 
HNRPF 1.365 0.050 21 
 
HSPB1 1.363 0.127 5 
 
RBMX;RMXL1 1.363 0.062 22 
 
RL5 1.356 0.237 6 
 
K1C10 1.356 0.152 58 
 
K1C14 1.354 0.091 43 
 
EMB 1.354 0.141 1 
 
RS4X;RS4Y1 1.354 0.050 19 
 
RS2 1.353 0.115 13 
 
RL1D1 1.353 0.103 2 
 
SRSF7 1.351 0.026 9 
 
MYL6 1.349 0.139 3 
 
ZN638 1.349 0.035 2 
 
K1C28;K1C27 1.345 0.034 16 
 
TBA1A;TBA1B 1.344 0.196 24 
 
NOP56 1.337 0.120 4 
 
ADT4 1.335 0.069 6 
 
PWP2B 1.334 0.013 6 
 
RS3 1.334 0.243 18 
 
K1C18 1.333 0.181 51 
 
RL35A 1.329 0.099 4 
 
RAN 1.322 0.105 13 
 
ILF2 1.318 0.281 4 
 
RL6 1.315 0.174 17 
 
RL36A 1.315 0.365 1 
 
TBB4B;TBB8 1.314 0.175 22 
 
RL13 1.314 0.175 15 
 
RL10A 1.310 0.211 16 
 
K2C80 1.305 0.526 2 
 
SRSF1 1.304 0.234 14 
 
ATPA 1.303 0.029 13 
 
RL40;RS27A 1.298 0.620 2 
 
RL35 1.296 0.141 6 
 
DDX5 1.292 0.188 26 
 
K2C5 1.289 0.179 42 
 




CP013 1.280 0.114 2 
 
TRA2B 1.280 0.180 8 
 
FBRL 1.277 0.118 11 
 
RL12 1.273 0.250 12 
 
RAB10;RAB13 1.271 0.240 2 
 
K2C78 1.268 0.288 12 
 
RS23 1.265 0.095 1 
 
K1C26 1.257 0.421 4 
 
HSP7C 1.255 0.044 10 
 
SRSF5 1.254 0.048 3 
 
NFL 1.241 0.049 11 
 
CL076 1.236 0.214 2 
 
EMD 1.234 0.219 1 
 
H12;H13 1.222 0.304 7 
 
SFPQ 1.217 0.210 14 
 
RS20 1.216 0.271 4 
 
H31T;H31 1.215 0.291 4 
 
RBM14 1.212 0.240 11 
 
RAB5C 1.206 0.443 2 
 
RAB37;RAB12 1.205 0.041 3 
 
K2C71 1.205 0.337 18 
 
PCBP2;PCBP3 1.203 0.210 5 
 
K1C12 1.202 0.327 17 
 
TBB5 1.196 0.226 21 
 
RL23 1.192 0.000 7 
 
GFAP 1.185 0.335 17 
 
NFH 1.182 0.259 17 
 
RL17 1.177 0.284 7 
 
RL31 1.176 0.078 7 
 
ROA0 1.173 0.144 12 
 
SRSF3 1.163 0.187 5 
 
LRC59 1.159 0.344 3 
 
RLA0 1.157 0.194 16 
 
UTP23 1.154 0.291 3 
 
KT33B 1.154 0.260 7 
 
1433Z 1.149 0.610 2 
 
KV403;KV401 1.132 0.482 13 
 
RS5 1.131 0.327 10 
 
SYDC 1.126 0.337 12 
 
AGO2 1.117 0.687 25 
 




K2C1B 1.116 0.460 22 
 
RL27A 1.102 0.188 6 
 
K22E 1.100 0.625 65 
 
RL23A 1.097 0.547 7 
 
RL27 1.093 0.649 9 
 
KV306 1.085 0.663 7 
 
HNRDL 1.081 0.736 18 
 
MCUR1 1.077 0.611 1 
 
H2A3;H2A1 1.076 0.623 9 
 
KV113 1.067 0.732 10 
 
RS10 1.060 0.847 2 
 
NTHL1 1.057 0.704 1 
 
K1H2 1.057 0.862 8 
 
PCBP1 1.055 0.787 6 
 
RS27L 1.054 0.788 1 
 
YTHD3 1.044 0.838 7 
 
K1C16 1.042 0.861 31 
 
DDX17 1.039 0.774 33 
 
NTPCR 1.033 0.814 2 
 
K2C75 1.028 0.903 38 
 
RS16 1.016 0.898 17 
 
ROA1 1.012 0.927 20 
 
TBB2A;TBB2B 1.001 0.997 18 
 
HDAC8 1.000 0.998 134 
 
TIAR 0.979 0.815 7 
 
RS14 0.966 0.811 5 
 
GBLP 0.957 0.764 8 
 
HNRPM 0.956 0.795 45 
 
CDK3 0.955 0.683 2 
 
RMXL3 0.939 0.744 4 
 
LAP2B 0.939 0.704 12 
 
HNRPQ 0.919 0.587 13 
 
RS12 0.906 0.252 6 
 
RS18 0.903 0.484 28 
 
TANC2 0.894 0.784 6 
 
VIME 0.893 0.356 94 
 
K1C13 0.857 0.367 21 
 
K2C6B 0.833 0.354 45 
 
K2C8;KRT81 0.833 0.210 105 
 
RLA1 0.820 0.357 1 
 




DDX3Y 0.759 0.107 8 
 
SLMAP 0.749 0.285 5 
 
RL7A 0.747 0.198 22 
 
TBB6 0.671 0.004 4 
 
RS19 0.648 0.024 9 
 
N2DL4 0.617 0.007 1 
 
SPR1A 0.552 0.171 1 
 
SYEP 0.502 0.161 17 
 
K2C6A 0.460 0.021 43 
 
SYIC 0.372 0.007 10 
 
LEG7 0.337 0.054 6 
 
ALBU 0.230 0.000 37 
 
NDUB4 0.211 0.017 1 
 
RAB3A 0.044 0.000 1 
 
RL26 0.000 0.000 8 Undefined due to zero unique 
peptides and overflow 
abundance* 
TBB4A 0.000 0.000 15 Undefined due to zero unique 
peptides and overflow 
abundance* 
K1C15 0.000 0.000 18 Undefined due to zero unique 
peptides and overflow 
abundance* 
ACTBL 0.000 0.000 15 Undefined due to zero unique 
peptides and overflow 
abundance* 
KRT83 0.000 0.000 4 Undefined due to zero unique 
peptides and overflow 
abundance* 
TBB3 0.000 0.000 14 Undefined due to zero unique 
peptides and overflow 
abundance* 
DUX5 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
RLA0L 0.000 0.000 12 Undefined due to zero unique 
peptides and overflow 
abundance* 
H90B3 0.000 0.000 3 Undefined due to zero unique 
peptides and overflow 
abundance* 
K2C6C 0.000 0.000 42 Undefined due to zero unique 
peptides and overflow 
abundance* 
RAB43;RB43L 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
CHCH3 0.000 0.000 1 Undefined due to zero unique 




KV201;KV206 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
TMCC3 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
NOP58 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
TBA3E 0.000 0.000 18 Undefined due to zero unique 
peptides and overflow 
abundance* 
RAB3D 0.000 0.000 2 Undefined due to zero unique 
peptides and overflow 
abundance* 
H90B2 0.000 0.000 2 Undefined due to zero unique 
peptides and overflow 
abundance* 
 
Table A1.3 - Proteins identified through HDAC8 covalent capture - F191 









RS9 6.087 0.013 1 
 
ROA1;RA1L2 3.911 0.001 3 
 
IL6 3.745 0.005 3 
 
SRSF3 3.661 0.000 1 
 
TIAR 2.507 0.000 3 
 
ATPB 2.105 0.003 4 
 
HNRPF 2.073 0.101 2 
 
FBRL 2.066 0.013 2 
 
RAB1C;RAB1A;RAB1B 1.981 0.005 1 
 
ROAA 1.976 0.008 7 
 
ILF2 1.862 0.018 1 
 
CKAP4 1.838 0.021 1 
 
OAT 1.776 0.026 6 
 
THIL 1.727 0.289 1 
 
RL4 1.654 0.016 6 
 
SERPH 1.561 0.000 7 
 
TBB2A;TBB2B;TBB6 1.550 0.019 10 
 
RS7 1.547 0.005 7 
 
HNRDL 1.529 0.048 5 
 
TBB4B;TBB4A;TBB8 1.527 0.009 16 
 
RLA1 1.499 0.054 2 
 
TBA1B;TBA1A;TBA1C 1.486 0.006 17 
 




RLA0 1.457 0.119 2 
 
ACTBM 1.457 0.078 9 
 
RL30 1.452 0.095 3 
 
RL35 1.452 0.193 5 
 




1.394 0.014 14 
 
RL6 1.372 0.007 12 
 
RS29 1.367 0.035 3 
 
ADT2 1.359 0.077 3 
 
AN18A 1.353 0.001 1 
 
H3C;H31;H31T;H32;H33 1.351 0.023 7 
 
RT23 1.346 0.387 1 
 
RL8 1.335 0.109 8 
 
HSPB1 1.324 0.040 5 
 
K1C18 1.312 0.089 5 
 
SFPQ 1.281 0.511 2 
 
TBB5 1.275 0.142 15 
 
RL17 1.268 0.370 2 
 
HDAC8 1.262 0.082 25 
 
RLA2 1.259 0.075 9 
 
RL7 1.259 0.253 3 
 
RL27 1.257 0.009 2 
 
GRP78 1.233 0.186 5 
 
ELAV1 1.211 0.557 3 
 
RS20 1.208 0.599 1 
 
RL19 1.207 0.337 5 
 
RL32 1.207 0.361 7 
 
RS3A 1.194 0.030 7 
 
RS16 1.185 0.808 1 
 
H2B1K;H2B1A;H2B1B 1.182 0.367 12 
 
ETFA 1.174 0.037 6 
 
RL14 1.167 0.491 2 
 
RL38 1.154 0.389 4 
 
VIME;KRT81;KRT83;KRT86 1.145 0.358 23 
 
TAGAP 1.143 0.224 2 
 
RL23A 1.140 0.206 5 
 




1.124 0.566 9 
 
RS5 1.100 0.565 3 
 




PHB 1.084 0.492 4 
 
FUBP2 1.079 0.524 27 
 
ROA3 1.079 0.792 2 
 
P4K2A 1.072 0.711 3 
 
H2A1J;H2A1;H2A1B 1.070 0.473 11 
 
H4 1.060 0.650 17 
 
RL18 1.057 0.751 5 
 
RS3 1.056 0.488 4 
 
ACTB;ACTA;ACTBL 1.051 0.672 16 
 
STAU1 1.050 0.817 5 
 
DAZP1 1.050 0.787 8 
 
TIF1B 1.033 0.663 4 
 
ROA2 1.030 0.876 6 
 
ATP5H 1.027 0.886 3 
 
RS2 1.021 0.922 9 
 
RBM14 1.020 0.907 6 
 
CH60 1.006 0.939 56 
 
HNRPC;HNRC1;HNRC2; 1.006 0.977 10 
 
DHX9 1.003 0.991 2 
 
RL23 1.000 0.998 6 
 
RL3 0.999 0.997 9 
 
SREK1 0.999 0.995 5 
 
UBQL1;UBQL4 0.998 0.987 2 
 
ATPA 0.988 0.939 22 
 
K2C5 0.982 0.905 5 
 
AINX 0.975 0.783 2 
 
MKX 0.971 0.576 4 
 
FUBP3 0.963 0.785 24 
 
RS28 0.963 0.755 5 
 
RL31 0.955 0.825 2 
 
PABP1 0.954 0.804 6 
 
HNRH3 0.952 0.851 5 
 
RS4X;RS4Y1;RS4Y2 0.951 0.523 9 
 
ADH1_YEAST 0.943 0.702 9 
 
RS19 0.937 0.610 13 
 
STML2 0.925 0.666 2 
 
H14;H11;H12;H13 0.921 0.499 24 
 
TRAP1 0.919 0.507 1 
 
GFAP 0.914 0.619 3 
 
TNIP2 0.909 0.491 1 
 




HNRPM 0.894 0.398 41 
 
RS18 0.893 0.458 9 
 
RL15 0.891 0.634 2 
 
RS11 0.891 0.670 6 
 
GRP75 0.888 0.391 14 
 
HNRH1;HNRH2 0.888 0.225 10 
 
IF2B1 0.888 0.462 5 
 
CDK1 0.885 0.317 5 
 
RL34 0.884 0.647 3 
 
DDX5 0.879 0.382 5 
 
RL11 0.869 0.403 5 
 
MATR3 0.869 0.338 15 
 
RL27A 0.860 0.438 10 
 
RL10A 0.858 0.105 7 
 
RLA0L 0.854 0.533 2 
 
RALYL 0.848 0.706 1 
 
RL13 0.846 0.112 14 
 
CERKL 0.841 0.011 2 
 
COX41 0.841 0.432 1 
 
RL7A 0.835 0.210 16 
 
HNRPD 0.832 0.135 6 
 
RL28 0.832 0.351 2 
 
RL3L 0.830 0.048 5 
 
RS8 0.825 0.098 8 
 
RBM4 0.824 0.222 4 
 
HNRPU 0.824 0.297 18 
 
NPM 0.819 0.042 16 
 
PSB2 0.817 0.296 3 
 
RS14 0.810 0.215 7 
 
EIF3F 0.809 0.138 1 
 
RS25 0.803 0.064 7 
 
RS12 0.799 0.134 4 
 
RS30 0.787 0.355 2 
 
ATPO 0.786 0.215 2 
 
NSUN2 0.783 0.066 9 
 
H2AY 0.782 0.253 1 
 
COX5B 0.779 0.292 4 
 
G3P 0.779 0.319 1 
 
RL9_MACFA;RL9 0.766 0.157 3 
 
EF1A2 0.763 0.020 10 
 




PCBP1 0.760 0.476 2 
 
MYL6 0.754 0.037 2 
 
RL24 0.749 0.227 4 
 
PB2_I56A3 0.748 0.004 3 
 
CX6B1 0.744 0.316 1 
 
LMNB1 0.743 0.000 16 
 
EFTU 0.739 0.012 17 
 
K2C8;K22O;K2C3 0.728 0.168 15 
 
KV404;KV401;KV402;KV403 0.725 0.168 4 
 
ODPB 0.715 0.022 6 
 
RL12 0.697 0.186 3 
 
RS6 0.694 0.021 9 
 
HS71A;HS71B;HSP76 0.693 0.069 14 
 
PRDX4 0.664 0.322 1 
 
VP35_EBOSU 0.655 0.025 1 
 
KV310;KV113;KV306 0.645 0.033 6 
 
RM12 0.628 0.131 5 
 
RL36 0.628 0.028 2 
 
PGS1 0.618 0.001 1 
 
RMXL1;RBMX 0.592 0.005 3 
 
RAB7A 0.587 0.037 4 
 
RL22 0.576 0.114 2 
 
FUBP1 0.470 0.103 5 
 
SLIRP 0.452 0.020 2 
 
TIA1 0.445 0.210 2 
 
ITB1 0.439 0.202 3 
 
IKBP1 0.387 0.015 1 
 
RL13A 0.385 0.067 2 
 
CB044 0.222 0.067 2 
 
LMNA 0.132 0.360 1 
 
GLYM 0.099 0.278 1 
 
K2C78 0.017 0.075 2 
 
LR10B 0.002 0.161 4 
 
XPO2 0.000 0.000 2 Undefined due to zero unique 
peptides and overflow 
abundance* 
TBA4A 0.000 0.000 12 Undefined due to zero unique 
peptides and overflow 
abundance* 
K2C79 0.000 0.000 4 Undefined due to zero unique 




K2C6B;K2C75 0.000 0.000 4 Undefined due to zero unique 
peptides and overflow 
abundance* 
HS71L 0.000 0.000 5 Undefined due to zero unique 
peptides and overflow 
abundance* 
CK040 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
YAED1 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
TBB3 0.000 0.000 8 Undefined due to zero unique 
peptides and overflow 
abundance* 
RL36A 0.000 0.000 1 Undefined due to zero unique 
peptides and overflow 
abundance* 
 
